US6811779B2
(en)
|
1994-02-10 |
2004-11-02 |
Imclone Systems Incorporated |
Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy
|
TW321649B
(enrdf_load_html_response)
*
|
1994-11-12 |
1997-12-01 |
Zeneca Ltd |
|
GB9424233D0
(en)
*
|
1994-11-30 |
1995-01-18 |
Zeneca Ltd |
Quinazoline derivatives
|
GB9508565D0
(en)
*
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quiazoline derivative
|
GB9508535D0
(en)
*
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quinazoline derivative
|
DE69613367T2
(de)
*
|
1995-04-27 |
2002-04-18 |
Astrazeneca Ab, Soedertaelje |
Chinazolin derivate
|
GB9508537D0
(en)
*
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quinazoline derivatives
|
US7060808B1
(en)
*
|
1995-06-07 |
2006-06-13 |
Imclone Systems Incorporated |
Humanized anti-EGF receptor monoclonal antibody
|
GB9624482D0
(en)
*
|
1995-12-18 |
1997-01-15 |
Zeneca Phaema S A |
Chemical compounds
|
PT880508E
(pt)
|
1996-02-13 |
2003-07-31 |
Astrazeneca Ab |
Derivados de quinazolina como inibidores de vegf
|
GB9603097D0
(en)
*
|
1996-02-14 |
1996-04-10 |
Zeneca Ltd |
Quinazoline compounds
|
GB9603095D0
(en)
*
|
1996-02-14 |
1996-04-10 |
Zeneca Ltd |
Quinazoline derivatives
|
CN1116286C
(zh)
|
1996-03-05 |
2003-07-30 |
曾尼卡有限公司 |
4-苯胺基喹唑啉衍生物
|
CN1145614C
(zh)
|
1996-04-12 |
2004-04-14 |
沃尼尔·朗伯公司 |
酪氨酸激酶的不可逆抑制剂,其制药用途及药物组合物
|
GB9607729D0
(en)
*
|
1996-04-13 |
1996-06-19 |
Zeneca Ltd |
Quinazoline derivatives
|
GB9718972D0
(en)
*
|
1996-09-25 |
1997-11-12 |
Zeneca Ltd |
Chemical compounds
|
AU737092B2
(en)
†
|
1997-08-15 |
2001-08-09 |
Cephalon, Inc. |
Combination of tyrosine kinase inhibitor and chemical castration to treat prostate cancer
|
ES2289791T3
(es)
|
1997-08-22 |
2008-02-01 |
Astrazeneca Ab |
Derivados de oxindolilquinazolina como inhibidores de la angiogenesis.
|
US20030224001A1
(en)
*
|
1998-03-19 |
2003-12-04 |
Goldstein Neil I. |
Antibody and antibody fragments for inhibiting the growth of tumors
|
US6864227B1
(en)
|
1998-04-13 |
2005-03-08 |
California Institute Of Technology |
Artery-and vein-specific proteins and uses therefor
|
US6887674B1
(en)
*
|
1998-04-13 |
2005-05-03 |
California Institute Of Technology |
Artery- and vein-specific proteins and uses therefor
|
ZA200007412B
(en)
*
|
1998-05-15 |
2002-03-12 |
Imclone Systems Inc |
Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases.
|
CZ2001584A3
(cs)
|
1998-08-18 |
2002-06-12 |
The Regents Of The University Of California |
Prevence tvorby hlenu v dýchacích cestách podáváním antagonistů EGF-R
|
US7354894B2
(en)
*
|
1998-08-18 |
2008-04-08 |
The Regents Of The University Of California |
Preventing airway mucus production by administration of EGF-R antagonists
|
IL141434A0
(en)
|
1998-08-21 |
2002-03-10 |
Parker Hughes Inst |
Quinazoline derivatives
|
US6288082B1
(en)
|
1998-09-29 |
2001-09-11 |
American Cyanamid Company |
Substituted 3-cyanoquinolines
|
US6297258B1
(en)
|
1998-09-29 |
2001-10-02 |
American Cyanamid Company |
Substituted 3-cyanoquinolines
|
CZ303681B6
(cs)
|
1998-09-29 |
2013-03-06 |
Wyeth Holdings Corporation |
Substituované deriváty 3-kyanochinolinu jako inhibitory proteintyrosinkináz
|
WO2000030673A1
(en)
*
|
1998-11-20 |
2000-06-02 |
Genentech, Inc. |
Uses for eph receptor antagonists and agonists to treat vascular disorders
|
CZ20013079A3
(cs)
|
1999-02-27 |
2001-11-14 |
Boehringer Ingelheim Pharma Kg |
Deriváty 4-aminochinazolinu a chinolinu
|
DE19911509A1
(de)
*
|
1999-03-15 |
2000-09-21 |
Boehringer Ingelheim Pharma |
Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
|
CZ20014083A3
(cs)
*
|
1999-05-14 |
2002-08-14 |
Imclone Systems Incorporated |
Léčivo pro indikaci růstu refrakterních nádorů
|
YU90901A
(sh)
|
1999-06-21 |
2004-07-15 |
Boehringer Ingelheim Pharma Gmbh. & Co.Kg. |
Biciklični heterocikli, lekovi koji sadrže ta jedinjenja, njihova primena i postupci za njihovo pripremanje
|
US6432979B1
(en)
|
1999-08-12 |
2002-08-13 |
American Cyanamid Company |
Method of treating or inhibiting colonic polyps and colorectal cancer
|
GB9925958D0
(en)
*
|
1999-11-02 |
1999-12-29 |
Bundred Nigel J |
Therapeutic use
|
NZ518028A
(en)
*
|
1999-11-05 |
2004-03-26 |
Astrazeneca Ab |
Quinazoline derivatives as VEGF inhibitors
|
US20020002169A1
(en)
|
1999-12-08 |
2002-01-03 |
Griffin John H. |
Protein kinase inhibitors
|
GB0002952D0
(en)
*
|
2000-02-09 |
2000-03-29 |
Pharma Mar Sa |
Process for producing kahalalide F compounds
|
GB0007371D0
(en)
|
2000-03-28 |
2000-05-17 |
Astrazeneca Uk Ltd |
Chemical compounds
|
GB0008368D0
(en)
*
|
2000-04-06 |
2000-05-24 |
Astrazeneca Ab |
Combination product
|
CN1240688C
(zh)
|
2000-04-07 |
2006-02-08 |
阿斯特拉曾尼卡有限公司 |
喹唑啉化合物
|
EP1170011A1
(en)
*
|
2000-07-06 |
2002-01-09 |
Boehringer Ingelheim International GmbH |
Novel use of inhibitors of the epidermal growth factor receptor
|
JP2004527456A
(ja)
*
|
2000-08-09 |
2004-09-09 |
イムクローン システムズ インコーポレイティド |
Egf受容体拮抗剤による過増殖性の疾患の治療
|
DE10042058A1
(de)
*
|
2000-08-26 |
2002-03-07 |
Boehringer Ingelheim Pharma |
Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
|
DE10042059A1
(de)
*
|
2000-08-26 |
2002-03-07 |
Boehringer Ingelheim Pharma |
Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
|
US6403580B1
(en)
|
2000-08-26 |
2002-06-11 |
Boehringer Ingelheim Pharma Kg |
Quinazolines, pharmaceutical compositions containing these compounds, their use and processes for preparing them
|
US6656946B2
(en)
|
2000-08-26 |
2003-12-02 |
Boehringer Ingelheim Pharma Kg |
Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases
|
US6617329B2
(en)
|
2000-08-26 |
2003-09-09 |
Boehringer Ingelheim Pharma Kg |
Aminoquinazolines and their use as medicaments
|
US6740651B2
(en)
|
2000-08-26 |
2004-05-25 |
Boehringer Ingelheim Pharma Kg |
Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases
|
WO2002030926A1
(en)
*
|
2000-10-13 |
2002-04-18 |
Astrazeneca Ab |
Quinazoline derivatives
|
ES2282299T3
(es)
|
2000-10-20 |
2007-10-16 |
EISAI R&D MANAGEMENT CO., LTD. |
Compuestos aromaticos con anillos de nitrogeno como agentes anticancerigenos.
|
DE10206505A1
(de)
*
|
2002-02-16 |
2003-08-28 |
Boehringer Ingelheim Pharma |
Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und EGFR-Kinase-Hemmern
|
US7776315B2
(en)
|
2000-10-31 |
2010-08-17 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Pharmaceutical compositions based on anticholinergics and additional active ingredients
|
EP1330444B1
(en)
|
2000-11-01 |
2011-03-23 |
Millennium Pharmaceuticals, Inc. |
Nitrogenous heterocyclic compounds and process for making them
|
US7019012B2
(en)
|
2000-12-20 |
2006-03-28 |
Boehringer Ingelheim International Pharma Gmbh & Co. Kg |
Quinazoline derivatives and pharmaceutical compositions containing them
|
LT2269604T
(lt)
|
2001-02-19 |
2016-11-10 |
Novartis Ag |
Inkstų solidinių navikų gydymas rapamicino dariniu
|
US20080008704A1
(en)
*
|
2001-03-16 |
2008-01-10 |
Mark Rubin |
Methods of treating colorectal cancer with anti-epidermal growth factor antibodies
|
AU2002342335B2
(en)
|
2001-05-16 |
2006-02-02 |
Novartis Ag |
Combination comprising N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2pyrimidine-amine and a chemotherapeutic agent
|
US7132427B2
(en)
|
2001-06-21 |
2006-11-07 |
Ariad Pharmaceuticals, Inc. |
Quinazolines and uses thereof
|
DE60234125D1
(de)
*
|
2001-12-24 |
2009-12-03 |
Astrazeneca Ab |
E inhibitoren
|
DE10204462A1
(de)
*
|
2002-02-05 |
2003-08-07 |
Boehringer Ingelheim Pharma |
Verwendung von Tyrosinkinase-Inhibitoren zur Behandlung inflammatorischer Prozesse
|
JP4389205B2
(ja)
|
2002-02-06 |
2009-12-24 |
宇部興産株式会社 |
4−アミノキナゾリン化合物の製法
|
GB0204392D0
(en)
*
|
2002-02-26 |
2002-04-10 |
Astrazeneca Ab |
Pharmaceutical compound
|
ATE465738T1
(de)
|
2002-02-26 |
2010-05-15 |
Astrazeneca Ab |
Neue kristalline formen der krebsbekämpfenden verbindung zd1839
|
DE60313956T2
(de)
*
|
2002-02-26 |
2008-05-15 |
Astrazeneca Ab |
Pharmazeutische iressa zusammensetzung enthaltend ein wasserlösliches cellulosederivat
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
GB0206215D0
(en)
|
2002-03-15 |
2002-05-01 |
Novartis Ag |
Organic compounds
|
RU2345989C2
(ru)
*
|
2002-03-28 |
2009-02-10 |
Астразенека Аб |
Производные 4-анилино-хиназолина, способ их получения (варианты), фармацевтическая композиция, способ ингибирования пролиферативного действия и способ лечения рака у теплокровного животного
|
TWI324597B
(en)
*
|
2002-03-28 |
2010-05-11 |
Astrazeneca Ab |
Quinazoline derivatives
|
US6924285B2
(en)
|
2002-03-30 |
2005-08-02 |
Boehringer Ingelheim Pharma Gmbh & Co. |
Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
|
BR0309226A
(pt)
*
|
2002-04-16 |
2005-02-09 |
Astrazeneca Ab |
Métodos para a produção de um efeito de danificação vascular em um animal de sangue quente, e para o tratamento de um câncer envolvendo um tumor sólido em um animal de sangue quente, composição farmacêutica, kit, e, usos de zd6126 ou de um seu sal farmaceuticamente aceitável, e de zd1839 ou de um seu sal farmaceuticamente aceitável
|
WO2005117986A2
(en)
|
2004-06-01 |
2005-12-15 |
Genentech, Inc. |
Antibody drug conjugates and methods
|
DE10221018A1
(de)
*
|
2002-05-11 |
2003-11-27 |
Boehringer Ingelheim Pharma |
Verwendung von Hemmern der EGFR-vermittelten Signaltransduktion zur Behandlung von gutartiger Prostatahyperplasie (BPH)/Prostatahypertrophie
|
JP5227492B2
(ja)
|
2002-05-16 |
2013-07-03 |
ノバルティス アーゲー |
癌におけるedgレセプター結合剤の使用
|
US20040048887A1
(en)
*
|
2002-07-09 |
2004-03-11 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Pharmaceutical compositions based on anticholinergics and EGFR kinase inhibitors
|
PT1585966E
(pt)
|
2002-07-15 |
2012-02-20 |
Hoffmann La Roche |
Tratamento de cancro com o anticorpo anti-erbb2 rhumab 2c4
|
CA2491191C
(en)
*
|
2002-07-15 |
2014-02-04 |
Exelixis, Inc. |
Receptor-type kinase modulators and methods of use
|
GB0221245D0
(en)
*
|
2002-09-13 |
2002-10-23 |
Astrazeneca Ab |
Chemical process
|
EP3321282A1
(en)
|
2002-09-27 |
2018-05-16 |
Xencor, Inc. |
Optimized fc variants and methods for their generation
|
GB0223854D0
(en)
*
|
2002-10-12 |
2002-11-20 |
Astrazeneca Ab |
Therapeutic treatment
|
GB0304367D0
(en)
*
|
2003-02-26 |
2003-04-02 |
Pharma Mar Sau |
Methods for treating psoriasis
|
DK1562955T3
(da)
*
|
2002-11-04 |
2008-06-02 |
Astrazeneca Ab |
Quinazolinderivater som Src-tyrosinkinaseinhibitorer
|
CA2506503A1
(en)
|
2002-11-20 |
2004-06-03 |
Array Biopharma, Inc. |
Cyanoguanidines and cyanoamidines as erbb2 and egfr inhibitors
|
WO2004060400A1
(ja)
*
|
2003-01-06 |
2004-07-22 |
Mitsubishi Pharma Corp |
上皮成長因子受容体を分子標的とする抗精神病薬
|
GEP20084540B
(en)
|
2003-01-14 |
2008-11-25 |
Arena Pharm Inc |
1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prpphylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
|
GB0302882D0
(en)
*
|
2003-02-07 |
2003-03-12 |
Univ Cardiff |
Improvements in or relating to agents for the treatment of cardiovascular dysfunction and weight loss
|
US7223749B2
(en)
|
2003-02-20 |
2007-05-29 |
Boehringer Ingelheim International Gmbh |
Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
|
JPWO2004080462A1
(ja)
|
2003-03-10 |
2006-06-08 |
エーザイ株式会社 |
c−Kitキナーゼ阻害剤
|
US7381410B2
(en)
*
|
2003-03-12 |
2008-06-03 |
Vasgene Therapeutics, Inc. |
Polypeptide compounds for inhibiting angiogenesis and tumor growth
|
AU2004220459B2
(en)
*
|
2003-03-12 |
2010-08-05 |
Vasgene Therapeutics, Inc. |
Polypeptide compounds for inhibiting angiogenesis and tumor growth
|
EP1622941A2
(en)
*
|
2003-03-20 |
2006-02-08 |
ImClone Systems Incorporated |
Method of producing an antibody to epidermal growth factor receptor
|
GB0309850D0
(en)
|
2003-04-30 |
2003-06-04 |
Astrazeneca Ab |
Quinazoline derivatives
|
GB0310401D0
(en)
*
|
2003-05-07 |
2003-06-11 |
Astrazeneca Ab |
Therapeutic agent
|
MY150088A
(en)
|
2003-05-19 |
2013-11-29 |
Irm Llc |
Immunosuppressant compounds and compositions
|
AR044402A1
(es)
|
2003-05-19 |
2005-09-14 |
Irm Llc |
Compuestos heterociclicos y su uso como inmunodepresores. composiciones farmaceuticas que los contienen.
|
JO2785B1
(en)
|
2003-05-27 |
2014-03-15 |
شركة جانسين فارماسوتيكا ان. في |
Quinazoline derivatives
|
KR101126560B1
(ko)
|
2003-05-30 |
2012-04-05 |
도꾜 다이가꾸 |
약제 반응 예측 방법
|
DE10326186A1
(de)
*
|
2003-06-06 |
2004-12-23 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
|
CN1972712A
(zh)
|
2003-06-09 |
2007-05-30 |
塞缪尔·瓦克萨尔 |
用胞外拮抗物和胞内拮抗物抑制受体酪氨酸激酶的方法
|
AR045047A1
(es)
|
2003-07-11 |
2005-10-12 |
Arena Pharm Inc |
Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
|
PT1648998E
(pt)
|
2003-07-18 |
2014-11-04 |
Amgen Inc |
Agentes de ligação específica ao factor de crescimento do hepatócito
|
GB0317665D0
(en)
|
2003-07-29 |
2003-09-03 |
Astrazeneca Ab |
Qinazoline derivatives
|
GB0317663D0
(en)
*
|
2003-07-29 |
2003-09-03 |
Astrazeneca Ab |
Pharmaceutical composition
|
MXPA06001079A
(es)
*
|
2003-07-29 |
2006-04-11 |
Astrazeneca Ab |
Derivados de piperidil quinazolina como inhibidores de cinasa de tirosina.
|
KR100953246B1
(ko)
*
|
2003-08-14 |
2010-04-16 |
어레이 바이오파마 인크. |
수용체 티로신 키나아제 억제제로서의 퀴나졸린 유사체
|
GB0320793D0
(en)
*
|
2003-09-05 |
2003-10-08 |
Astrazeneca Ab |
Chemical process
|
GB0321066D0
(en)
*
|
2003-09-09 |
2003-10-08 |
Pharma Mar Sau |
New antitumoral compounds
|
ATE395346T1
(de)
|
2003-09-16 |
2008-05-15 |
Astrazeneca Ab |
Chinazolinderivate als tyrosinkinaseinhibitoren
|
WO2005026156A1
(en)
*
|
2003-09-16 |
2005-03-24 |
Astrazeneca Ab |
Quinazoline derivatives
|
WO2005028469A1
(en)
*
|
2003-09-19 |
2005-03-31 |
Astrazeneca Ab |
Quinazoline derivatives
|
WO2005028470A1
(en)
*
|
2003-09-19 |
2005-03-31 |
Astrazeneca Ab |
Quinazoline derivatives
|
WO2005030757A1
(en)
*
|
2003-09-25 |
2005-04-07 |
Astrazeneca Ab |
Quinazoline derivatives
|
GB0322409D0
(en)
|
2003-09-25 |
2003-10-29 |
Astrazeneca Ab |
Quinazoline derivatives
|
DK2392565T3
(da)
*
|
2003-09-26 |
2014-05-05 |
Exelixis Inc |
c-Met-modulatorer og anvendelsesfremgangsmåder
|
US7456189B2
(en)
|
2003-09-30 |
2008-11-25 |
Boehringer Ingelheim International Gmbh |
Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation
|
DE10349113A1
(de)
|
2003-10-17 |
2005-05-12 |
Boehringer Ingelheim Pharma |
Verfahren zur Herstellung von Aminocrotonylverbindungen
|
ZA200603619B
(en)
|
2003-11-06 |
2008-10-29 |
Seattle Genetics Inc |
Monomethylvaline compounds capable of conjugation to ligands
|
US7683172B2
(en)
|
2003-11-11 |
2010-03-23 |
Eisai R&D Management Co., Ltd. |
Urea derivative and process for preparing the same
|
GB0326459D0
(en)
|
2003-11-13 |
2003-12-17 |
Astrazeneca Ab |
Quinazoline derivatives
|
MXPA06007017A
(es)
|
2003-12-18 |
2006-08-31 |
Janssen Pharmaceutica Nv |
Derivados de pirido y pirimidopirimidina como agentes antiproliferativos.
|
AU2003290345A1
(en)
*
|
2003-12-24 |
2005-07-14 |
Astrazeneca Ab |
Pharmaceutical dissolution testing using a non-ionic surfactant
|
WO2005070909A1
(en)
*
|
2004-01-22 |
2005-08-04 |
Natco Pharma Limited |
An improved process for the preparation of gefitinib
|
DE602005010824D1
(de)
|
2004-02-03 |
2008-12-18 |
Astrazeneca Ab |
Chinazolinderivate
|
ATE492564T1
(de)
|
2004-03-12 |
2011-01-15 |
Vasgene Therapeutics Inc |
Ephb4-bindende antikörper zur inhibierung von angiogenese und tumorwachstum
|
NZ549787A
(en)
*
|
2004-03-12 |
2010-05-28 |
Vasgene Therapeutics Inc |
Antibodies binding to EphB4 for inhibiting angiogenesis and tumor growth
|
EP2332990A1
(en)
|
2004-03-19 |
2011-06-15 |
Imclone LLC |
Human anti-epidermal growth factor receptor antibody
|
JP4350148B2
(ja)
|
2004-03-31 |
2009-10-21 |
ザ ジェネラル ホスピタル コーポレイション |
上皮細胞成長因子受容体ターゲティング治療に対する癌の応答性を決定する方法
|
WO2005097134A2
(en)
*
|
2004-03-31 |
2005-10-20 |
The Scripps Research Institute |
Quinazoline based protein kinase inhibitors
|
PE20060166A1
(es)
|
2004-04-07 |
2006-04-25 |
Novartis Ag |
Derivados de amida como inhibidores de proteinas de apoptosis (iap)
|
CA2565721C
(en)
|
2004-05-06 |
2015-10-06 |
Bioresponse, L.L.C. |
Diindolymethane formulations for the treatment of leiomyomas
|
KR100885835B1
(ko)
*
|
2004-05-06 |
2009-02-26 |
워너-램버트 캄파니 엘엘씨 |
4-페닐아미노-퀴나졸린-6-일-아미드
|
GB0512324D0
(en)
|
2005-06-16 |
2005-07-27 |
Novartis Ag |
Organic compounds
|
EP2277595A3
(en)
|
2004-06-24 |
2011-09-28 |
Novartis Vaccines and Diagnostics, Inc. |
Compounds for immunopotentiation
|
EP1919950A1
(en)
|
2004-07-15 |
2008-05-14 |
Xencor, Inc. |
Optimized fc variants
|
KR20070053205A
(ko)
|
2004-09-17 |
2007-05-23 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
의약 조성물
|
EP1799713B1
(en)
*
|
2004-09-23 |
2014-11-05 |
VasGene Therapeutics, Inc. |
Polypeptide compounds for inhibiting angiogenesis and tumor growth
|
AU2005286607B2
(en)
|
2004-09-23 |
2011-01-27 |
Genentech, Inc. |
Cysteine engineered antibodies and conjugates
|
JO3000B1
(ar)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
JP2008521900A
(ja)
|
2004-11-30 |
2008-06-26 |
アムジエン・インコーポレーテツド |
キノリン及びキナゾリン類似体並びにがん治療のための医薬としてのその使用
|
NI200700147A
(es)
|
2004-12-08 |
2019-05-10 |
Janssen Pharmaceutica Nv |
Derivados de quinazolina inhibidores de cinasas dirigidos a multip
|
JO3088B1
(ar)
*
|
2004-12-08 |
2017-03-15 |
Janssen Pharmaceutica Nv |
مشتقات كوينازولين كبيرة الحلقات و استعمالها بصفتها موانع كينيز متعددة الاهداف
|
US7947676B2
(en)
|
2004-12-14 |
2011-05-24 |
Astrazeneca Ab |
Pyrazolo[3,4-d]pyrimidine compounds as antitumor agents
|
CA2593084C
(en)
|
2004-12-30 |
2014-03-18 |
Bioresponse, Llc |
Use of diindolylmethane-related indoles for the treatment and prevention of respiratory syncytial virus associated conditions
|
DOP2006000010A
(es)
|
2005-01-10 |
2006-07-31 |
Arena Pharm Inc |
Procedimiento para preparar eteres aromáticos
|
KR101345002B1
(ko)
|
2005-01-21 |
2013-12-31 |
아스텍스 테라퓨틱스 리미티드 |
제약 화합물
|
KR20150083139A
(ko)
|
2005-01-21 |
2015-07-16 |
제넨테크, 인크. |
Her 항체의 고정 용량 투여법
|
GB0501999D0
(en)
*
|
2005-02-01 |
2005-03-09 |
Sentinel Oncology Ltd |
Pharmaceutical compounds
|
AU2006210572B2
(en)
|
2005-02-03 |
2011-08-04 |
The General Hospital Corporation |
Method for treating gefitinib resistant cancer
|
US20060188498A1
(en)
*
|
2005-02-18 |
2006-08-24 |
Genentech, Inc. |
Methods of using death receptor agonists and EGFR inhibitors
|
US20090155247A1
(en)
*
|
2005-02-18 |
2009-06-18 |
Ashkenazi Avi J |
Methods of Using Death Receptor Agonists and EGFR Inhibitors
|
RU2404806C2
(ru)
|
2005-02-23 |
2010-11-27 |
Дженентек, Инк. |
Продление времени до прогрессирования заболевания или продолжительности жизни у онкологических больных с применением ингибиторов димеризации her
|
WO2006090413A1
(en)
*
|
2005-02-23 |
2006-08-31 |
Natco Pharma Limited |
Novel crystalline form of gefitinib and a process for its preparation
|
AU2006217738A1
(en)
|
2005-02-26 |
2006-08-31 |
Astrazeneca Ab |
Quinazoline derivatives as tyrosine kinase inhibitors
|
JPWO2006090930A1
(ja)
*
|
2005-02-28 |
2008-07-24 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
スルホンアミド化合物の新規併用
|
US20060216288A1
(en)
*
|
2005-03-22 |
2006-09-28 |
Amgen Inc |
Combinations for the treatment of cancer
|
EP1871345B1
(en)
*
|
2005-04-12 |
2012-08-01 |
Elan Pharma International Limited |
Nanoparticulate erlotinib formulations
|
AR054252A1
(es)
|
2005-04-19 |
2007-06-13 |
Smithkline Beecham Cork Ltd |
Composicion farmaceutica oral que contiene sales de ditosilato de 4-quinazolinamina
|
CN101175733A
(zh)
*
|
2005-05-12 |
2008-05-07 |
黄文林 |
一种酪氨酸激酶抑制剂、其制备方法及作为抗肿瘤药物的应用
|
WO2006119673A1
(fr)
*
|
2005-05-12 |
2006-11-16 |
Wenlin Huang |
Procede de preparation de derives de quinazoline et application pour la fabrication pour le traitement d’une maladie tumorale
|
CN101175734B
(zh)
*
|
2005-05-12 |
2011-10-12 |
黄文林 |
一种作为抗肿瘤药物的喹唑啉衍生物及其制备方法
|
DK1885187T3
(da)
|
2005-05-13 |
2013-12-09 |
Novartis Ag |
Fremgangsmåde til behandling af lægemiddelresistent cancer
|
GB0510390D0
(en)
|
2005-05-20 |
2005-06-29 |
Novartis Ag |
Organic compounds
|
KR101246504B1
(ko)
|
2005-06-17 |
2013-03-26 |
임클론 엘엘씨 |
항-PDGFRα 항체
|
US7557190B2
(en)
|
2005-07-08 |
2009-07-07 |
Xencor, Inc. |
Optimized proteins that target Ep-CAM
|
NZ587586A
(en)
*
|
2005-07-18 |
2012-04-27 |
Bipar Sciences Inc |
Treatment of cancer
|
US20100105031A1
(en)
*
|
2005-08-01 |
2010-04-29 |
Esai R & D Management Co., Ltd. |
Method for prediction of the efficacy of vascularization inhibitor
|
JP4989476B2
(ja)
|
2005-08-02 |
2012-08-01 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
血管新生阻害物質の効果を検定する方法
|
EP1917528B1
(en)
|
2005-08-24 |
2011-08-17 |
Bristol-Myers Squibb Company |
Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators
|
CN1300118C
(zh)
*
|
2005-08-25 |
2007-02-14 |
江苏吴中苏药医药开发有限责任公司 |
4-(3-氯-4-氟苯基胺基)-7-甲氧基-6-(3-吗啉丙氧基)喹唑啉的制备方法
|
WO2007026864A1
(ja)
*
|
2005-09-01 |
2007-03-08 |
Eisai R & D Management Co., Ltd. |
崩壊性の改善された医薬組成物の製造方法
|
JP2009508918A
(ja)
|
2005-09-20 |
2009-03-05 |
アストラゼネカ アクチボラグ |
癌治療のためのerbB受容体チロシンキナーゼ阻害剤としての4−(1H−インダゾール−5−イル]アミノ)キナゾリン化合物
|
EP1937291A2
(en)
*
|
2005-09-23 |
2008-07-02 |
Vasgene Therapeutics, Inc. |
Use of ephrinb2 directed agents for the treatment of prevention of viral infections
|
RU2451524C2
(ru)
|
2005-11-04 |
2012-05-27 |
Вайет |
Противоопухолевые комбинации с ингибиторами mtor, герцептином и/или hki-272
|
CA2627598C
(en)
|
2005-11-07 |
2013-06-25 |
Eisai R & D Management Co., Ltd. |
Use of combination of anti-angiogenic substance and c-kit kinase inhibitor
|
EP1948179A1
(en)
|
2005-11-11 |
2008-07-30 |
Boehringer Ingelheim International GmbH |
Quinazoline derivatives for the treatment of cancer diseases
|
DK2275103T3
(da)
|
2005-11-21 |
2014-07-07 |
Novartis Ag |
mTor-inhibitorer ved behandling af endokrine tumorer
|
WO2007061127A1
(ja)
*
|
2005-11-22 |
2007-05-31 |
Eisai R & D Management Co., Ltd. |
多発性骨髄腫に対する抗腫瘍剤
|
US7977346B2
(en)
*
|
2006-01-17 |
2011-07-12 |
Guoqing Paul Chen |
Spiro compounds and methods of use
|
JO2660B1
(en)
|
2006-01-20 |
2012-06-17 |
نوفارتيس ايه جي |
Pi-3 inhibitors and methods of use
|
CN101003514A
(zh)
*
|
2006-01-20 |
2007-07-25 |
上海艾力斯医药科技有限公司 |
喹唑啉衍生物、其制备方法及用途
|
AR059066A1
(es)
|
2006-01-27 |
2008-03-12 |
Amgen Inc |
Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
|
PE20070978A1
(es)
*
|
2006-02-14 |
2007-11-15 |
Novartis Ag |
COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks)
|
GB0605120D0
(en)
|
2006-03-14 |
2006-04-26 |
Novartis Ag |
Organic Compounds
|
US20070231298A1
(en)
*
|
2006-03-31 |
2007-10-04 |
Cell Genesys, Inc. |
Cytokine-expressing cancer immunotherapy combinations
|
BRPI0709749A2
(pt)
|
2006-04-05 |
2011-07-26 |
Novartis Ag |
combinaÇÕes de agentes terapÊuticos para tratamento de cÂncer
|
CN102671196B
(zh)
|
2006-04-05 |
2014-12-03 |
诺华股份有限公司 |
用于治疗癌症的治疗剂的组合
|
TW200808739A
(en)
*
|
2006-04-06 |
2008-02-16 |
Novartis Vaccines & Diagnostic |
Quinazolines for PDK1 inhibition
|
CN101472915A
(zh)
|
2006-04-19 |
2009-07-01 |
诺瓦提斯公司 |
吲唑化合物和抑制cdc7的方法
|
AR060635A1
(es)
|
2006-04-27 |
2008-07-02 |
Banyu Pharma Co Ltd |
Derivados de 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-ona, composiciones farmaceuticas que los comprenden y su uso en el tratamiento del cancer
|
EP2026800A1
(en)
|
2006-05-09 |
2009-02-25 |
Novartis AG |
Combination comprising an iron chelator and an anti-neoplastic agent and use thereof
|
ES2556173T3
(es)
|
2006-05-18 |
2016-01-13 |
Eisai R&D Management Co., Ltd. |
Agente antitumoral para un cáncer de tiroides
|
WO2008147418A1
(en)
*
|
2006-06-12 |
2008-12-04 |
Bipar Sciences, Inc. |
Method of treating diseases with parp inhibitors
|
US20100279327A1
(en)
*
|
2006-06-12 |
2010-11-04 |
Bipar Sciences, Inc. |
Method of treating diseases with parp inhibitors
|
JPWO2008001956A1
(ja)
*
|
2006-06-29 |
2009-12-03 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
肝線維症治療剤
|
MX2009000456A
(es)
|
2006-07-13 |
2009-01-27 |
Janssen Pharmaceutica Nv |
Derivados de quinazolina mtki.
|
US8217177B2
(en)
|
2006-07-14 |
2012-07-10 |
Amgen Inc. |
Fused heterocyclic derivatives and methods of use
|
PE20080403A1
(es)
|
2006-07-14 |
2008-04-25 |
Amgen Inc |
Derivados heterociclicos fusionados y metodos de uso
|
WO2008022152A2
(en)
|
2006-08-14 |
2008-02-21 |
Xencor, Inc. |
Optimized antibodies that target cd19
|
WO2008026748A1
(fr)
|
2006-08-28 |
2008-03-06 |
Eisai R & D Management Co., Ltd. |
Agent antitumoral pour cancer gastrique non différencié
|
JP2008081492A
(ja)
|
2006-08-31 |
2008-04-10 |
Banyu Pharmaceut Co Ltd |
オーロラa選択的阻害作用を有する新規アミノピリジン誘導体
|
WO2008030883A2
(en)
*
|
2006-09-05 |
2008-03-13 |
Bipar Sciences, Inc. |
Treatment of cancer
|
AU2007292306A1
(en)
*
|
2006-09-05 |
2008-03-13 |
Bipar Sciences, Inc. |
Inhibition of fatty acid synthesis by PARP inhibitors and methods of treatment thereof
|
US7977347B2
(en)
*
|
2006-09-11 |
2011-07-12 |
Curis, Inc. |
Quinazoline based EGFR inhibitors
|
EP2845912A1
(en)
|
2006-09-12 |
2015-03-11 |
Genentech, Inc. |
Methods and compositions for the diagnosis and treatment of lung cancer using KIT gene as genetic marker
|
SI2068880T1
(sl)
|
2006-09-18 |
2012-08-31 |
Boehringer Ingelheim Int |
Postopek za zdravljenje raka, ki vsebuje mutacije EGFR
|
ATE502943T1
(de)
|
2006-09-29 |
2011-04-15 |
Novartis Ag |
Pyrazolopyrimidine als pi3k-lipidkinasehemmer
|
WO2008044045A1
(en)
|
2006-10-12 |
2008-04-17 |
Astex Therapeutics Limited |
Pharmaceutical combinations
|
JP5528806B2
(ja)
|
2006-10-12 |
2014-06-25 |
アステックス、セラピューティックス、リミテッド |
複合薬剤
|
WO2008046242A1
(fr)
*
|
2006-10-16 |
2008-04-24 |
Institute Of Mataria Medica, Chinese Academy Of Medical Sciences |
Nouveaux dérivés quinazolines, leurs procédés de préparation et leurs utilisations
|
US8586621B2
(en)
|
2006-10-27 |
2013-11-19 |
Michael A. Zeligs |
Anti-parasitic methods and compositions utilizing diindolylmethane-related indoles
|
MX2009004437A
(es)
*
|
2006-10-27 |
2009-05-11 |
Janssen Pharmaceutica Nv |
El uso de un inhibidor de cinasa de multiples objetivos para el tratamiento o la prevencion del cancer cerebral.
|
US7851623B2
(en)
|
2006-11-02 |
2010-12-14 |
Astrazeneca Ab |
Chemical process
|
EP1921070A1
(de)
|
2006-11-10 |
2008-05-14 |
Boehringer Ingelheim Pharma GmbH & Co. KG |
Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
|
BRPI0720032A2
(pt)
*
|
2006-12-13 |
2013-12-17 |
Gilead Sciences Inc |
Composto e sais farmaceuticamente aceitáveis dos mesmos, processo, formulação de aerossol, método para a prevenção e tratamento de inflamação pulmonar ou broncoconstrição, e, uso de um composto.
|
US7687522B2
(en)
|
2006-12-20 |
2010-03-30 |
Amgen Inc. |
Substituted pyridines and pyrimidines and their use in treatment of cancer
|
US7977336B2
(en)
|
2006-12-28 |
2011-07-12 |
Banyu Pharmaceutical Co. Ltd |
Aminopyrimidine derivatives as PLK1 inhibitors
|
ES2449482T3
(es)
|
2007-01-09 |
2014-03-19 |
Amgen Inc. |
Derivados de bis-aril-amida útiles para el tratamiento de cáncer
|
WO2008093855A1
(ja)
|
2007-01-29 |
2008-08-07 |
Eisai R & D Management Co., Ltd. |
未分化型胃癌治療用組成物
|
JP5377332B2
(ja)
|
2007-02-06 |
2013-12-25 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
二環式へテロ環、それらの化合物を含む薬剤、その使用及びその製法
|
AU2008216327A1
(en)
|
2007-02-15 |
2008-08-21 |
Novartis Ag |
Combination of LBH589 with other therapeutic agents for treating cancer
|
JP2010519204A
(ja)
|
2007-02-16 |
2010-06-03 |
アムジエン・インコーポレーテツド |
窒素含有複素環ケトン類およびそれらのc−Met阻害薬としての使用
|
PE20090681A1
(es)
|
2007-03-02 |
2009-06-10 |
Genentech Inc |
Prediccion de respuesta a un inhibidor her
|
US20100292209A1
(en)
*
|
2007-03-30 |
2010-11-18 |
Massachusetts Institute Of Technology |
Methods for identifying compounds that modulate neurotrophic factor signaling
|
NZ580382A
(en)
|
2007-04-16 |
2012-05-25 |
Cipla Ltd |
Process for the preparation of gefitinib
|
EP2176298B1
(en)
|
2007-05-30 |
2017-11-15 |
Xencor, Inc. |
Methods and compositions for inhibiting cd32b expressing cells
|
ES2417148T3
(es)
|
2007-06-08 |
2013-08-06 |
Genentech, Inc. |
Marcadores de expresión génica de la resistencia tumoral al tratamiento con inhibidor de HER2
|
ES2435454T3
(es)
*
|
2007-06-21 |
2013-12-19 |
Janssen Pharmaceutica, N.V. |
Indolin-2-onas y aza-indolin-2-onas
|
JP5536647B2
(ja)
|
2007-07-27 |
2014-07-02 |
ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ |
ピロロピリミジン
|
EP2185594B1
(en)
*
|
2007-08-13 |
2016-04-06 |
VasGene Therapeutics, Inc. |
Cancer treatment using humanized antibodies that bind to ephb4
|
NO2188313T3
(enrdf_load_html_response)
|
2007-08-21 |
2018-03-31 |
|
|
JP5474792B2
(ja)
*
|
2007-09-10 |
2014-04-16 |
キュリス,インコーポレイテッド |
亜鉛結合部分を含むキナゾリンベースegfrインヒビターの酒石酸塩またはその複合体
|
US8022216B2
(en)
|
2007-10-17 |
2011-09-20 |
Wyeth Llc |
Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
|
NZ584695A
(en)
*
|
2007-10-19 |
2011-06-30 |
Pharma Mar Sa |
Improved antitumoral treatments using PM02734 and an EGFR tyrosine kinase inhibitor (erlotinib)
|
EP2211854A4
(en)
*
|
2007-10-19 |
2011-01-12 |
Bipar Sciences Inc |
METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER USING BENZOPYRONE-TYPE PARP INHIBITORS
|
JPWO2009054332A1
(ja)
|
2007-10-23 |
2011-03-03 |
萬有製薬株式会社 |
ピリドン置換ジヒドロピラゾロピリミジノン誘導体
|
EA018716B1
(ru)
*
|
2007-10-29 |
2013-10-30 |
Натко Фарма Лимитед |
Новые 4-(тетразол-5-ил) хиназолиновые производные в качестве противораковых средств
|
EP2218712B1
(en)
|
2007-11-09 |
2015-07-01 |
Eisai R&D Management Co., Ltd. |
Combination of anti-angiogenic substance and anti-tumor platinum complex
|
KR20100102607A
(ko)
*
|
2007-11-12 |
2010-09-24 |
바이파 사이언스 인코포레이티드 |
Parp 억제제를 단독으로 사용하거나 항종양제와 병용하여 자궁암 및 난소암을 치료하는 방법
|
CA2705537A1
(en)
*
|
2007-11-12 |
2009-05-22 |
Bipar Sciences, Inc. |
Treatment of breast cancer with a parp inhibitor alone or in combination with anti-tumor agents
|
WO2009067543A2
(en)
*
|
2007-11-19 |
2009-05-28 |
The Regents Of The University Of Colorado |
Treatment of histone deacetylase mediated disorders
|
CL2008003449A1
(es)
|
2007-11-21 |
2010-02-19 |
Imclone Llc |
Anticuerpo o fragmentos del mismo contra el receptor de proteína estimulante de macrófagos/ron; composición farmacéutica que lo comprende; uso para inhibir angiogénesis, crecimiento tumoral, proliferación, migración e invasión de células tumorales, activación de ron o fosforilación de mapk y/o akt; y uso para tratar cáncer.
|
CA2708157A1
(en)
*
|
2007-12-07 |
2009-06-11 |
Bipar Sciences, Inc. |
Treatment of cancer with combinations of topoisomerase inhibitors and parp inhibitors
|
EP2240475B1
(en)
|
2007-12-20 |
2013-09-25 |
Novartis AG |
Thiazole derivatives used as pi 3 kinase inhibitors
|
ES2642159T3
(es)
|
2008-01-18 |
2017-11-15 |
Natco Pharma Limited |
Proceso para la preparación de derivados de 6,7-dialcoxi-quinazolina
|
WO2009094216A1
(en)
*
|
2008-01-22 |
2009-07-30 |
Concert Pharmaceuticals Inc. |
Derivatives of gefitinib
|
KR101506062B1
(ko)
*
|
2008-01-29 |
2015-03-25 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
혈관 저해 물질과 탁산의 병용
|
US20100323021A1
(en)
*
|
2008-01-30 |
2010-12-23 |
Pharma Mar, S.A. |
Antitumoral treatments
|
TWI472339B
(zh)
|
2008-01-30 |
2015-02-11 |
Genentech Inc |
包含結合至her2結構域ii之抗體及其酸性變異體的組合物
|
RS52573B
(en)
|
2008-02-07 |
2013-04-30 |
Boehringer Ingelheim International Gmbh |
SPIROCYCLIC HETEROCYCLES, THE MEDICINAL PRODUCTS CONTAINING THIS UNIT, THEIR APPLICATION AND THE PROCEDURE FOR THEIR MANUFACTURING
|
BRPI0908049A2
(pt)
*
|
2008-03-05 |
2015-08-11 |
Novartis Ag |
Uso de derivados de pririmidina para o tratamento de doenças dependentes de egfr ou de doenças que possuem resistência adquirida a agentes que são direcionados aos membros da família de egfr
|
MX2010009782A
(es)
*
|
2008-03-07 |
2010-09-30 |
Pharma Mar Sa |
Tratamientos antitumorales mejorados.
|
WO2009118292A1
(en)
|
2008-03-24 |
2009-10-01 |
Novartis Ag |
Arylsulfonamide-based matrix metalloprotease inhibitors
|
CN101544609A
(zh)
|
2008-03-25 |
2009-09-30 |
上海艾力斯医药科技有限公司 |
4-苯胺喹唑啉衍生物的结晶形式
|
MY150437A
(en)
|
2008-03-26 |
2014-01-30 |
Novartis Ag |
Hydroxamate-based inhibitors of deacetylases b
|
EA019183B1
(ru)
|
2008-05-13 |
2014-01-30 |
Астразенека Аб |
Фумаратная соль 4-(3-хлор-2-фторанилино)-7-метокси-6-{[1-(n-метилкарбамоилметил)пиперидин-4-ил]окси}хиназолина
|
EP2615183B1
(en)
|
2008-05-14 |
2014-10-08 |
Genomic Health, Inc. |
Predictors of patient response to treatment with EGF receptor inhibitors
|
CN101584696A
(zh)
|
2008-05-21 |
2009-11-25 |
上海艾力斯医药科技有限公司 |
包含喹唑啉衍生物的组合物及制备方法、用途
|
ES2431355T3
(es)
|
2008-06-17 |
2013-11-26 |
Wyeth Llc |
Combinaciones antineoplásicas que contienen HKI-272 y vinorelbina
|
DE102008031040A1
(de)
|
2008-06-30 |
2009-12-31 |
Alexander Priv.-Doz. Dr. Dömling |
Iressa zur Anwendung in der Organtransplantation
|
US8669273B2
(en)
|
2008-08-04 |
2014-03-11 |
Wyeth Llc |
Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine
|
US8648191B2
(en)
|
2008-08-08 |
2014-02-11 |
Boehringer Ingelheim International Gmbh |
Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them
|
CN101367793B
(zh)
*
|
2008-09-26 |
2013-09-11 |
中国科学院广州生物医药与健康研究院 |
一种具有抗肿瘤活性的氨基喹唑啉衍生物及其盐类
|
US20110223241A1
(en)
|
2008-10-16 |
2011-09-15 |
Celator Pharmaceuticals, Inc. |
Combination methods and compositions
|
WO2010054264A1
(en)
|
2008-11-07 |
2010-05-14 |
Triact Therapeutics, Inc. |
Use of catecholic butane derivatives in cancer therapy
|
EP2370082A4
(en)
*
|
2008-12-01 |
2012-05-30 |
Univ Central Florida Res Found |
FOR BELLY CANCER CELLS CYTOTOXIC DRUG COMPOSITION
|
HUE034819T2
(en)
|
2008-12-18 |
2018-02-28 |
Novartis Ag |
1- (4- {1 - [(E) -4-Cyclohexyl-3-trifluoromethyl-benzyloxyimino] -ethyl} -2-ethyl-benzyl) -azetidine-3-carboxylic acid hemifumarate salt for treatment of diseases mediated by lymphocytes
|
RU2011129230A
(ru)
|
2008-12-18 |
2013-01-27 |
Новартис Аг |
Новая полиморфная форма 1-[4-[1-(4-циклогексил-3-трифторметилбензилоксиимино)этил]-2-этилбензил]азетидин-3-карбоновой кислоты
|
CA2747558A1
(en)
|
2008-12-18 |
2010-07-15 |
Novartis Ag |
New salts
|
KR20230008268A
(ko)
|
2009-01-16 |
2023-01-13 |
엑셀리시스, 인코포레이티드 |
암의 치료를 위한 n-(4-{〔6,7-비스(메틸옥시)퀴놀린-4-일〕옥시}페닐)-n'-(4-플루오로페닐)사이클로프로판-1,1-디카르복사미드의 말산염 및 그 결정형
|
WO2010083617A1
(en)
|
2009-01-21 |
2010-07-29 |
Oncalis Ag |
Pyrazolopyrimidines as protein kinase inhibitors
|
HRP20121006T1
(hr)
|
2009-01-29 |
2013-01-31 |
Novartis Ag |
Supstituirani benzimidazoli za lijeäśenje astrocitoma
|
EP2400985A2
(en)
|
2009-02-25 |
2012-01-04 |
OSI Pharmaceuticals, LLC |
Combination of an either an anti-igf-1r antibody or an igf binding protein and a small molecule igf-1r kinase inhibitor
|
WO2010098367A1
(en)
|
2009-02-25 |
2010-09-02 |
Banyu Pharmaceutical Co.,Ltd. |
Pyrimidopyrimidoindazole derivative
|
JP2012519170A
(ja)
|
2009-02-26 |
2012-08-23 |
オーエスアイ・ファーマシューティカルズ,エルエルシー |
生体内の腫瘍細胞のemtステータスをモニターするためのinsitu法
|
EP2401614A1
(en)
|
2009-02-27 |
2012-01-04 |
OSI Pharmaceuticals, LLC |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
EP2401613A2
(en)
|
2009-02-27 |
2012-01-04 |
OSI Pharmaceuticals, LLC |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
WO2010099138A2
(en)
|
2009-02-27 |
2010-09-02 |
Osi Pharmaceuticals, Inc. |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
US8481503B2
(en)
|
2009-03-06 |
2013-07-09 |
Merck Sharp & Dohme Corp. |
Combination cancer therapy with an AKT inhibitor and other anticancer agents
|
EP2408479A1
(en)
|
2009-03-18 |
2012-01-25 |
OSI Pharmaceuticals, LLC |
Combination cancer therapy comprising administration of an egfr inhibitor and an igf-1r inhibitor
|
CN104447995A
(zh)
|
2009-03-20 |
2015-03-25 |
霍夫曼-拉罗奇有限公司 |
双特异性抗-her抗体
|
KR20190128004A
(ko)
|
2009-04-06 |
2019-11-13 |
와이어쓰 엘엘씨 |
네라티닙을 이용한 유방암의 치료법
|
WO2010120386A1
(en)
|
2009-04-17 |
2010-10-21 |
Nektar Therapeutics |
Oligomer-protein tyrosine kinase inhibitor conjugates
|
EA021011B1
(ru)
|
2009-06-26 |
2015-03-31 |
Новартис Аг |
1,3-ДИЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ ИМИДАЗОЛИДИН-2-ОНА В КАЧЕСТВЕ ИНГИБИТОРОВ Cyp 17
|
US8293753B2
(en)
|
2009-07-02 |
2012-10-23 |
Novartis Ag |
Substituted 2-carboxamide cycloamino ureas
|
US9545381B2
(en)
|
2009-07-06 |
2017-01-17 |
Boehringer Ingelheim International Gmbh |
Process for drying of BIBW2992, of its salts and of solid pharmaceutical formulations comprising this active ingredient
|
US9050341B2
(en)
*
|
2009-07-14 |
2015-06-09 |
Natco Pharma Limited |
Methods of treating drug resistant and other tumors by administering 6,7-dialkoxy quinazoline derivatives
|
US9345661B2
(en)
|
2009-07-31 |
2016-05-24 |
Genentech, Inc. |
Subcutaneous anti-HER2 antibody formulations and uses thereof
|
UA108618C2
(uk)
|
2009-08-07 |
2015-05-25 |
|
Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
|
US8389526B2
(en)
|
2009-08-07 |
2013-03-05 |
Novartis Ag |
3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
|
BR112012003262A8
(pt)
|
2009-08-12 |
2016-05-17 |
Novartis Ag |
compostos de hidrazona heterocíclica e seus usos para tratar câncer e inflamação
|
MX2012002066A
(es)
|
2009-08-17 |
2012-03-29 |
Intellikine Inc |
Compuestos heterociclicos y usos de los mismos.
|
JP5775871B2
(ja)
|
2009-08-20 |
2015-09-09 |
ノバルティス アーゲー |
ヘテロ環式オキシム化合物
|
CN102574785A
(zh)
|
2009-08-26 |
2012-07-11 |
诺瓦提斯公司 |
四取代的杂芳基化合物和它们作为mdm2和/或mdm4调节剂的用途
|
JP2013504543A
(ja)
|
2009-09-10 |
2013-02-07 |
ノバルティス アーゲー |
二環ヘテロアリール類のエーテル誘導体
|
WO2011053779A2
(en)
|
2009-10-30 |
2011-05-05 |
Bristol-Myers Squibb Company |
Methods for treating cancer in patients having igf-1r inhibitor resistance
|
NZ599565A
(en)
|
2009-11-04 |
2013-05-31 |
Novartis Ag |
Heterocyclic sulfonamide derivatives useful as mek inhibitors
|
JP2013510871A
(ja)
|
2009-11-12 |
2013-03-28 |
ジェネンテック, インコーポレイテッド |
樹状突起棘の密度を促す方法
|
US20120316187A1
(en)
|
2009-11-13 |
2012-12-13 |
Pangaea Biotech, S.L. |
Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer
|
BR112012012210B8
(pt)
|
2009-11-23 |
2021-05-25 |
Cerulean Pharma Inc |
conjugado de (cdp)-taxano de polímero contendo ciclodextrina, composição, composição farmacêutica, forma de dosagem, kit e uso de um conjugado de cdp-taxano
|
US20120289501A1
(en)
|
2009-11-25 |
2012-11-15 |
Novartis Ag |
Benzene-fused 6-membered oxygen-containing heterocyclic derivatives of bicyclic heteroaryls
|
RU2016105962A
(ru)
|
2009-12-04 |
2018-11-23 |
Дженентек, Инк. |
Мультиспецифические антитела, аналоги антител, композиции и способы
|
AU2012265844A1
(en)
|
2009-12-08 |
2013-05-02 |
Novartis Ag |
Heterocyclic sulfonamide derivatives
|
CA2781218A1
(en)
|
2009-12-08 |
2011-06-16 |
Novartis Ag |
Heterocyclic sulfonamide derivatives
|
US8440693B2
(en)
|
2009-12-22 |
2013-05-14 |
Novartis Ag |
Substituted isoquinolinones and quinazolinones
|
CU24130B1
(es)
|
2009-12-22 |
2015-09-29 |
Novartis Ag |
Isoquinolinonas y quinazolinonas sustituidas
|
CA2781578A1
(en)
|
2010-01-12 |
2011-07-21 |
F. Hoffmann-La Roche Ag |
Tricyclic heterocyclic compounds, compositions and methods of use thereof
|
WO2011090940A1
(en)
|
2010-01-19 |
2011-07-28 |
Cerulean Pharma Inc. |
Cyclodextrin-based polymers for therapeutic delivery
|
CN102146060B
(zh)
*
|
2010-02-09 |
2013-07-03 |
陕西师范大学 |
制备吉非替尼及其中间体的方法
|
CN102892779B
(zh)
|
2010-02-18 |
2016-12-21 |
基因泰克公司 |
神经调节蛋白拮抗剂及其在治疗癌症中的用途
|
WO2011107664A1
(en)
|
2010-03-04 |
2011-09-09 |
Hospital District Of Southwest Finland |
Method for selecting patients for treatment with an egfr inhibitor
|
JP2013522267A
(ja)
|
2010-03-17 |
2013-06-13 |
エフ.ホフマン−ラ ロシュ アーゲー |
イミダゾピリジン化合物、組成物、および使用法
|
WO2011119995A2
(en)
|
2010-03-26 |
2011-09-29 |
Cerulean Pharma Inc. |
Formulations and methods of use
|
CA2794745A1
(en)
|
2010-03-29 |
2011-10-06 |
Zymeworks, Inc. |
Antibodies with enhanced or suppressed effector function
|
TWI406853B
(zh)
*
|
2010-04-07 |
2013-09-01 |
Dev Center Biotechnology |
Egfr與vegfr-2雙重抑制劑及其用途與製法
|
EP2558864A1
(en)
|
2010-04-16 |
2013-02-20 |
Genentech, Inc. |
Fox03a as predictive biomarker for pi3k/akt kinase pathway inhibitor efficacy
|
WO2011146568A1
(en)
|
2010-05-19 |
2011-11-24 |
Genentech, Inc. |
Predicting response to a her inhibitor
|
JP2013528635A
(ja)
|
2010-06-17 |
2013-07-11 |
ノバルティス アーゲー |
ビフェニル置換1,3−ジヒドロ−ベンゾイミダゾール−2−イリデンアミン誘導体
|
WO2011157793A1
(en)
|
2010-06-17 |
2011-12-22 |
Novartis Ag |
Piperidinyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives
|
WO2011161217A2
(en)
|
2010-06-23 |
2011-12-29 |
Palacký University in Olomouc |
Targeting of vegfr2
|
AU2011270165B2
(en)
|
2010-06-25 |
2015-12-24 |
Eisai R&D Management Co., Ltd. |
Antitumor agent using compounds having kinase inhibitory effect in combination
|
UA112517C2
(uk)
|
2010-07-06 |
2016-09-26 |
Новартіс Аг |
Тетрагідропіридопіримідинові похідні
|
AR082418A1
(es)
|
2010-08-02 |
2012-12-05 |
Novartis Ag |
Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico
|
AU2011295919A1
(en)
|
2010-08-31 |
2013-03-07 |
Genentech, Inc. |
Biomarkers and methods of treatment
|
JP5822934B2
(ja)
|
2010-09-15 |
2015-11-25 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
アザベンゾチアゾール化合物、組成物及び使用方法
|
US8946260B2
(en)
|
2010-09-16 |
2015-02-03 |
Novartis Ag |
17α-hydroxylase/C17,20-lyase inhibitors
|
EP2619198A1
(en)
|
2010-09-22 |
2013-07-31 |
Arena Pharmaceuticals, Inc. |
Modulators of the gpr119 receptor and the treatment of disorders related thereto
|
WO2012065161A2
(en)
|
2010-11-12 |
2012-05-18 |
Scott & White Healthcare |
Antibodies to tumor endothelial marker 8
|
KR20140009259A
(ko)
|
2010-11-19 |
2014-01-22 |
에프. 호프만-라 로슈 아게 |
피라졸로피리딘 및 tyk2 억제제로서 이의 용도
|
EA201390611A1
(ru)
|
2010-11-24 |
2014-01-30 |
Глаксо Груп Лимитед |
Мультиспецифические антигенсвязывающие белки, направленные на hgf
|
JP2014500308A
(ja)
|
2010-12-21 |
2014-01-09 |
ノバルティス アーゲー |
Vps34阻害剤としてのビヘテロアリール化合物
|
EP2468883A1
(en)
|
2010-12-22 |
2012-06-27 |
Pangaea Biotech S.L. |
Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer
|
WO2012085176A1
(en)
|
2010-12-23 |
2012-06-28 |
F. Hoffmann-La Roche Ag |
Tricyclic pyrazinone compounds, compositions and methods of use thereof as janus kinase inhibitors
|
US9134297B2
(en)
|
2011-01-11 |
2015-09-15 |
Icahn School Of Medicine At Mount Sinai |
Method and compositions for treating cancer and related methods
|
PH12013501600A1
(en)
|
2011-01-31 |
2013-09-30 |
Novartis Ag |
Novel heterocyclic derivatives
|
JP2014505088A
(ja)
|
2011-02-10 |
2014-02-27 |
ノバルティス アーゲー |
C−METチロシンキナーゼ阻害剤としての[1,2,4]トリアゾロ[4,3−b]ピリダジン化合物
|
EP2492688A1
(en)
|
2011-02-23 |
2012-08-29 |
Pangaea Biotech, S.A. |
Molecular biomarkers for predicting response to antitumor treatment in lung cancer
|
US9127000B2
(en)
|
2011-02-23 |
2015-09-08 |
Intellikine, LLC. |
Heterocyclic compounds and uses thereof
|
SG10201601711SA
(en)
|
2011-03-04 |
2016-04-28 |
Newgen Therapeutics Inc |
Alkyne Substituted Quinazoline Compound And Methods Of Use
|
US20130338152A1
(en)
|
2011-03-08 |
2013-12-19 |
Irm Llc |
Fluorophenyl bicyclic heteroaryl compounds
|
US8609818B2
(en)
|
2011-03-10 |
2013-12-17 |
Omeros Corporation |
Generation of anti-FN14 monoclonal antibodies by ex-vivo accelerated antibody evolution
|
WO2012125904A1
(en)
|
2011-03-17 |
2012-09-20 |
The Trustees Of The University Of Pennsylvania |
Mutation mimicking compounds that bind to the kinase domain of egfr
|
WO2012125913A1
(en)
|
2011-03-17 |
2012-09-20 |
The Trustees Of The University Of Pennsylvania |
Methods and use of bifunctional enzyme-building clamp-shaped molecules
|
WO2012129145A1
(en)
|
2011-03-18 |
2012-09-27 |
OSI Pharmaceuticals, LLC |
Nscle combination therapy
|
JP5647374B2
(ja)
|
2011-03-23 |
2014-12-24 |
アムジエン・インコーポレーテツド |
Cdk4/6およびflt3の縮合三環系二重阻害剤
|
CN103402519B
(zh)
|
2011-04-18 |
2015-11-25 |
卫材R&D管理有限公司 |
肿瘤治疗剂
|
EP2702173A1
(en)
|
2011-04-25 |
2014-03-05 |
OSI Pharmaceuticals, LLC |
Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
|
GB201106870D0
(en)
|
2011-04-26 |
2011-06-01 |
Univ Belfast |
Marker
|
CA2834224A1
(en)
|
2011-04-28 |
2012-11-01 |
Novartis Ag |
17.alpha.-hydroxylase/c17,20-lyase inhibitors
|
CN102918029B
(zh)
|
2011-05-17 |
2015-06-17 |
江苏康缘药业股份有限公司 |
4-苯胺-6-丁烯酰胺-7-烷醚喹唑啉衍生物及其制备方法和用途
|
EP2714937B1
(en)
|
2011-06-03 |
2018-11-14 |
Eisai R&D Management Co., Ltd. |
Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
|
US8859586B2
(en)
|
2011-06-20 |
2014-10-14 |
Novartis Ag |
Cyclohexyl isoquinolinone compounds
|
EP2721008B1
(en)
|
2011-06-20 |
2015-04-29 |
Novartis AG |
Hydroxy substituted isoquinolinone derivatives as p53 (mdm2 or mdm4) inhibitors
|
SG195067A1
(en)
|
2011-06-27 |
2013-12-30 |
Novartis Ag |
Solid forms and salts of tetrahydro-pyrido-pyrimidine derivatives
|
CN107090038A
(zh)
|
2011-06-30 |
2017-08-25 |
霍夫曼-拉罗奇有限公司 |
抗c‑met抗体配制剂
|
WO2013007765A1
(en)
|
2011-07-13 |
2013-01-17 |
F. Hoffmann-La Roche Ag |
Fused tricyclic compounds for use as inhibitors of janus kinases
|
WO2013007768A1
(en)
|
2011-07-13 |
2013-01-17 |
F. Hoffmann-La Roche Ag |
Tricyclic heterocyclic compounds, compositions and methods of use thereof as jak inhibitors
|
JP5855253B2
(ja)
|
2011-08-12 |
2016-02-09 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
インダゾール化合物、組成物及び使用方法
|
CA2844289C
(en)
|
2011-08-12 |
2020-01-14 |
Omeros Corporation |
Anti-fzd10 monoclonal antibodies and methods for their use
|
WO2013025939A2
(en)
|
2011-08-16 |
2013-02-21 |
Indiana University Research And Technology Corporation |
Compounds and methods for treating cancer by inhibiting the urokinase receptor
|
EP2758043A4
(en)
|
2011-08-17 |
2016-02-24 |
Dennis M Brown |
COMPOSITIONS AND METHODS FOR INCREASING THE THERAPEUTIC UTILITY OF SUBOPTIMALLY APPLIED CHEMICAL COMPOUNDS INCLUDING SUBSTITUTED HEXITOLS SUCH AS DIBROMODULCITOL
|
MX2014001766A
(es)
|
2011-08-17 |
2014-05-01 |
Genentech Inc |
Anticuerpos de neuregulina y sus usos.
|
CN104024432B
(zh)
|
2011-08-31 |
2017-02-22 |
基因泰克公司 |
诊断性标志物
|
EP2755976B1
(en)
|
2011-09-15 |
2018-07-18 |
Novartis AG |
6-substituted 3-(quinolin-6-ylthio)-[1,2,4]triazolo[4,3-a]pyridines as c-met tyrosine kinase inhibitors
|
HK1198365A1
(en)
|
2011-09-20 |
2015-04-10 |
F. Hoffmann-La Roche Ag |
Imidazopyridine compounds, compositions and methods of use
|
CN103012290B
(zh)
*
|
2011-09-28 |
2015-05-13 |
齐鲁制药有限公司 |
一种高纯度吉非替尼的制备方法
|
CN104066851A
(zh)
|
2011-09-30 |
2014-09-24 |
基因泰克公司 |
肿瘤或肿瘤细胞中上皮或间充质表型的诊断性甲基化标志物和对egfr激酶抑制剂的响应
|
WO2013056069A1
(en)
|
2011-10-13 |
2013-04-18 |
Bristol-Myers Squibb Company |
Methods for selecting and treating cancer in patients with igf-1r/ir inhibitors
|
PH12014500912A1
(en)
|
2011-10-28 |
2014-06-09 |
Novartis Ag |
Novel purine derivatives and their use in the treatment of disease
|
TWI577671B
(zh)
*
|
2011-11-14 |
2017-04-11 |
Sunshine Lake Pharma Co Ltd |
Aminoquinazoline derivatives and salts thereof and methods of use thereof
|
CN103102345B
(zh)
*
|
2011-11-14 |
2015-06-03 |
广东东阳光药业有限公司 |
氨基喹唑啉类衍生物及其盐和使用方法
|
CN103102342B
(zh)
*
|
2011-11-14 |
2014-10-29 |
广东东阳光药业有限公司 |
氨基喹唑啉类衍生物及其盐和使用方法
|
US8969341B2
(en)
|
2011-11-29 |
2015-03-03 |
Novartis Ag |
Pyrazolopyrrolidine compounds
|
MX2014006529A
(es)
|
2011-11-30 |
2014-11-25 |
Genentech Inc |
Mutaciones de erbb3 en cancer.
|
US9408885B2
(en)
|
2011-12-01 |
2016-08-09 |
Vib Vzw |
Combinations of therapeutic agents for treating melanoma
|
CN103130729B
(zh)
*
|
2011-12-05 |
2015-07-15 |
齐鲁制药有限公司 |
一种4-氯代-7-甲氧基喹唑啉-6-醇乙酸酯的制备方法
|
CN103172576B
(zh)
*
|
2011-12-21 |
2015-08-05 |
沈阳药科大学 |
吉非替尼的苹果酸加成盐及其制备和应用
|
US20150148377A1
(en)
|
2011-12-22 |
2015-05-28 |
Novartis Ag |
Quinoline Derivatives
|
PL2794600T3
(pl)
|
2011-12-22 |
2018-06-29 |
Novartis Ag |
Pochodne 2,3-dihydro-benzo[1,4]oksazyny i powiązane związki jako inhibitory kinazy fosfoinozytydu-3 (PI3K) do leczenia np. reumatoidalnego zapalenia stawów
|
US20130178520A1
(en)
|
2011-12-23 |
2013-07-11 |
Duke University |
Methods of treatment using arylcyclopropylamine compounds
|
AU2012355613A1
(en)
|
2011-12-23 |
2014-07-17 |
Novartis Ag |
Compounds for inhibiting the interaction of BCL2 with binding partners
|
WO2013096060A1
(en)
|
2011-12-23 |
2013-06-27 |
Novartis Ag |
Compounds for inhibiting the interaction of bcl2 with binding partners
|
EA201491265A1
(ru)
|
2011-12-23 |
2014-11-28 |
Новартис Аг |
Соединения для ингибирования взаимодействия bcl-2 с партнерами по связыванию
|
WO2013096051A1
(en)
|
2011-12-23 |
2013-06-27 |
Novartis Ag |
Compounds for inhibiting the interaction of bcl2 with binding partners
|
KR20140104047A
(ko)
|
2011-12-23 |
2014-08-27 |
노파르티스 아게 |
Bcl2와 결합 파트너의 상호작용을 억제하기 위한 화합물
|
JO3357B1
(ar)
|
2012-01-26 |
2019-03-13 |
Novartis Ag |
مركبات إيميدازوبيروليدينون
|
KR20140117644A
(ko)
|
2012-01-31 |
2014-10-07 |
스미스클라인 비이참 (코르크) 리미티드 |
암을 치료하는 방법
|
NZ630020A
(en)
|
2012-03-08 |
2016-08-26 |
Halozyme Inc |
Conditionally active anti-epidermal growth factor receptor antibodies and methods of use thereof
|
AR090263A1
(es)
|
2012-03-08 |
2014-10-29 |
Hoffmann La Roche |
Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
|
US9193718B2
(en)
|
2012-03-26 |
2015-11-24 |
Fujian Institute Of Research On The Structure Of Matter, Chinese Academy Of Sciences |
Quinazoline derivative and application thereof
|
CN104220457A
(zh)
|
2012-03-27 |
2014-12-17 |
霍夫曼-拉罗奇有限公司 |
涉及her3抑制剂的诊断和治疗
|
US20150297604A1
(en)
|
2012-04-03 |
2015-10-22 |
Novartis Ag |
Combination Products with Tyrosine Kinase Inhibitors and their Use
|
WO2013152252A1
(en)
|
2012-04-06 |
2013-10-10 |
OSI Pharmaceuticals, LLC |
Combination anti-cancer therapy
|
CA2872526A1
(en)
|
2012-05-16 |
2013-11-21 |
Novartis Ag |
Dosage regimen for a pi-3 kinase inhibitor
|
EP2855483B1
(en)
|
2012-05-24 |
2017-10-25 |
Novartis AG |
Pyrrolopyrrolidinone compounds
|
KR101457453B1
(ko)
*
|
2012-05-31 |
2014-11-04 |
주식회사 종근당 |
게피티닙의 제조방법 및 이의 제조에 사용되는 중간체
|
JP6427097B2
(ja)
|
2012-06-15 |
2018-11-21 |
ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドThe Brigham and Women’s Hospital, Inc. |
癌を処置するための組成物および該組成物を製造するための方法
|
WO2013190089A1
(en)
|
2012-06-21 |
2013-12-27 |
Pangaea Biotech, S.L. |
Molecular biomarkers for predicting outcome in lung cancer
|
WO2014016848A2
(en)
|
2012-07-24 |
2014-01-30 |
Laurus Labs Private Limited |
Solid forms of tyrosine kinase inhibitors, process for the preparation and their pharmaceutical composition thereof
|
US9738643B2
(en)
|
2012-08-06 |
2017-08-22 |
Duke University |
Substituted indazoles for targeting Hsp90
|
EP2890696A1
(en)
|
2012-08-29 |
2015-07-08 |
Amgen, Inc. |
Quinazolinone compounds and derivatives thereof
|
WO2014071402A1
(en)
|
2012-11-05 |
2014-05-08 |
Dana-Farber Cancer Institute, Inc. |
Xbp1, cd138, and cs1, pharmaceutical compositions that include the peptides, and methods of using such petides and compositions
|
TW201422625A
(zh)
|
2012-11-26 |
2014-06-16 |
Novartis Ag |
二氫-吡啶并-□衍生物之固體形式
|
BR112015009004A8
(pt)
|
2012-12-21 |
2021-07-20 |
Eisai R&D Man Co Ltd |
forma amorfa de derivado de quinolina e método de produção da mesma
|
CN103073509A
(zh)
*
|
2012-12-31 |
2013-05-01 |
广东先强药业有限公司 |
一类喹唑啉衍生物的制备方法
|
CN103910690A
(zh)
*
|
2013-01-06 |
2014-07-09 |
上海科胜药物研发有限公司 |
一种吉非替尼新晶型及其制备方法
|
EP2943484B1
(en)
|
2013-01-10 |
2017-10-25 |
Glaxosmithkline Intellectual Property (No. 2) Limited |
Fatty acid synthase inhibitors
|
US9556180B2
(en)
|
2013-01-22 |
2017-01-31 |
Novartis Ag |
Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the P53/MDM2 interaction
|
WO2014115077A1
(en)
|
2013-01-22 |
2014-07-31 |
Novartis Ag |
Substituted purinone compounds
|
AU2014212242B2
(en)
|
2013-02-01 |
2017-12-21 |
Pharma Cinq, Llc |
Amine compounds having anti-inflammatory, antifungal, antiparasitic and anticancer activity
|
WO2014130657A1
(en)
|
2013-02-20 |
2014-08-28 |
The Trustees Of The University Of Pennsylvania |
Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor
|
WO2014128612A1
(en)
|
2013-02-20 |
2014-08-28 |
Novartis Ag |
Quinazolin-4-one derivatives
|
CN104994879A
(zh)
|
2013-02-22 |
2015-10-21 |
霍夫曼-拉罗奇有限公司 |
治疗癌症和预防药物抗性的方法
|
WO2014134202A1
(en)
|
2013-02-26 |
2014-09-04 |
Triact Therapeutics, Inc. |
Cancer therapy
|
US9468681B2
(en)
|
2013-03-01 |
2016-10-18 |
California Institute Of Technology |
Targeted nanoparticles
|
UA115686C2
(uk)
|
2013-03-06 |
2017-12-11 |
Астразенека Аб |
Хіназолінові інгібітори активувальних мутантних форм рецептора епідермального фактора росту
|
MX2015011428A
(es)
|
2013-03-06 |
2016-02-03 |
Genentech Inc |
Metodos para tratar y prevenir la resistencia a los farmacos para el cancer.
|
US20140275092A1
(en)
|
2013-03-13 |
2014-09-18 |
Constellation Pharmaceuticals, Inc. |
Pyrazolo compounds and uses thereof
|
SG11201507477XA
(en)
|
2013-03-14 |
2015-10-29 |
Genentech Inc |
Combinations of a mek inhibitor compound with an her3/egfr inhibitor compound and methods of use
|
PL2970205T3
(pl)
|
2013-03-14 |
2019-10-31 |
Tolero Pharmaceuticals Inc |
Inhibitory jak2 i alk2 oraz sposoby ich zastosowania
|
BR112015022604A2
(pt)
|
2013-03-14 |
2017-10-24 |
Genentech Inc |
usos de um modulador de modificador de cromatina e um antagonista de egfr
|
EP2968537A1
(en)
|
2013-03-15 |
2016-01-20 |
Genentech, Inc. |
Methods of treating cancer and preventing cancer drug resistance
|
JP2016512835A
(ja)
|
2013-03-15 |
2016-05-09 |
インテリカイン, エルエルシー |
キナーゼ阻害剤の組み合わせ及びそれらの使用
|
EP2976085A1
(en)
|
2013-03-21 |
2016-01-27 |
INSERM - Institut National de la Santé et de la Recherche Médicale |
Method and pharmaceutical composition for use in the treatment of chronic liver diseases associated with a low hepcidin expression
|
WO2014147631A1
(en)
|
2013-03-22 |
2014-09-25 |
Natco Pharma Limited |
Formulation comprising gefitinib as oral suspension
|
WO2014155268A2
(en)
|
2013-03-25 |
2014-10-02 |
Novartis Ag |
Fgf-r tyrosine kinase activity inhibitors - use in diseases associated with lack of or reduced snf5 activity
|
SG11201509278XA
(en)
|
2013-05-14 |
2015-12-30 |
Eisai R&D Man Co Ltd |
Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
|
US20150018376A1
(en)
|
2013-05-17 |
2015-01-15 |
Novartis Ag |
Pyrimidin-4-yl)oxy)-1h-indole-1-carboxamide derivatives and use thereof
|
CN103304491A
(zh)
*
|
2013-06-17 |
2013-09-18 |
连云港盛和生物科技有限公司 |
一种吉非替尼的制备方法
|
KR20150001936A
(ko)
*
|
2013-06-28 |
2015-01-07 |
제일약품주식회사 |
게피티닙의 신규한 결정형 및 이의 제조방법
|
UY35675A
(es)
|
2013-07-24 |
2015-02-27 |
Novartis Ag |
Derivados sustituidos de quinazolin-4-ona
|
WO2015017607A2
(en)
*
|
2013-08-02 |
2015-02-05 |
Cephalon, Inc. |
METHODS OF TREATING VARIOUS CANCERS USING AN AXL/cMET INHIBITOR ALONE OR IN COMBINATION WITH OTHER AGENTS
|
US9227969B2
(en)
|
2013-08-14 |
2016-01-05 |
Novartis Ag |
Compounds and compositions as inhibitors of MEK
|
WO2015022663A1
(en)
|
2013-08-14 |
2015-02-19 |
Novartis Ag |
Compounds and compositions as inhibitors of mek
|
WO2015022664A1
(en)
|
2013-08-14 |
2015-02-19 |
Novartis Ag |
Compounds and compositions as inhibitors of mek
|
CA2922925A1
(en)
|
2013-09-05 |
2015-03-12 |
Genentech, Inc. |
Antiproliferative compounds
|
US9381246B2
(en)
|
2013-09-09 |
2016-07-05 |
Triact Therapeutics, Inc. |
Cancer therapy
|
HK1226081A1
(zh)
|
2013-09-12 |
2017-09-22 |
Halozyme, Inc. |
修飾的抗表皮生長因子受體抗體及其使用方法
|
WO2015159118A2
(en)
|
2013-09-17 |
2015-10-22 |
Obi Pharma, Inc. |
Compositions of a carbohydrate vaccine for inducing immune responses and uses thereof in cancer treatment
|
BR112016003229A8
(pt)
|
2013-09-22 |
2020-02-04 |
Calitor Sciences Llc |
composto, composição farmacêutica, e, uso de um composto ou de uma composição farmacêutica
|
CN104513253A
(zh)
*
|
2013-10-01 |
2015-04-15 |
南京波尔泰药业科技有限公司 |
用于治疗增殖性疾病的大环化合物
|
AR097894A1
(es)
|
2013-10-03 |
2016-04-20 |
Hoffmann La Roche |
Inhibidores terapéuticos de cdk8 o uso de los mismos
|
TWI658052B
(zh)
|
2013-10-18 |
2019-05-01 |
美商建南德克公司 |
抗-rspo抗體及使用方法
|
WO2015084804A1
(en)
|
2013-12-03 |
2015-06-11 |
Novartis Ag |
Combination of mdm2 inhibitor and braf inhibitor and their use
|
ES2899167T3
(es)
|
2013-12-06 |
2022-03-10 |
Novartis Ag |
Régimen posológico para un inhibidor de fosfatidilinositol 3-cinasas selectivo para la isoforma alfa
|
WO2015095418A1
(en)
|
2013-12-17 |
2015-06-25 |
Genentech, Inc. |
Methods of treating her2-positive cancers using pd-1 axis binding antagonists and anti-her2 antibodies
|
EP3083687A2
(en)
|
2013-12-17 |
2016-10-26 |
F. Hoffmann-La Roche AG |
Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
|
US9242965B2
(en)
|
2013-12-31 |
2016-01-26 |
Boehringer Ingelheim International Gmbh |
Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors
|
WO2015128837A1
(en)
|
2014-02-26 |
2015-09-03 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Methods of treating cancer patients responding to ezh2 inhibitor gsk126
|
KR20160137599A
(ko)
|
2014-03-24 |
2016-11-30 |
제넨테크, 인크. |
C-met 길항제로의 암 치료 및 이것과 hgf 발현과의 상관관계
|
WO2015148714A1
(en)
|
2014-03-25 |
2015-10-01 |
Duke University |
Heat shock protein 70 (hsp-70) receptor ligands
|
WO2015145388A2
(en)
|
2014-03-27 |
2015-10-01 |
Novartis Ag |
Methods of treating colorectal cancers harboring upstream wnt pathway mutations
|
JP6538148B2
(ja)
|
2014-03-28 |
2019-07-03 |
キャリター・サイエンシーズ・リミテッド・ライアビリティ・カンパニーCalitor Sciences, Llc |
置換されたヘテロアリール化合物および使用方法
|
AU2015241038A1
(en)
|
2014-03-31 |
2016-10-13 |
Genentech, Inc. |
Combination therapy comprising anti-angiogenesis agents and OX40 binding agonists
|
EP3632934A1
(en)
|
2014-03-31 |
2020-04-08 |
F. Hoffmann-La Roche AG |
Anti-ox40 antibodies and methods of use
|
JP2017513931A
(ja)
|
2014-04-03 |
2017-06-01 |
インビクタス オンコロジー ピーヴィティー.リミテッド |
超分子コンビナトリアル治療薬
|
US20170027940A1
(en)
|
2014-04-10 |
2017-02-02 |
Stichting Het Nederlands Kanker Instituut |
Method for treating cancer
|
WO2015170345A1
(en)
|
2014-05-09 |
2015-11-12 |
Council Of Scientific & Industrial Research |
Pharmaceutical cocrystals of gefitinib
|
RU2577518C2
(ru)
*
|
2014-06-02 |
2016-03-20 |
Олег Ростиславович Михайлов |
КРИСТАЛЛИЧЕСКАЯ БЕЗВОДНАЯ γ-МОДИФИКАЦИЯ 4-(3'-ХЛОР-4'-ФТОРАНИЛИНО)-7-МЕТОКСИ-6-(3-МОРФОЛИНОПРОПОКСИ)ХИНАЗОЛИНА, СПОСОБ ЕЕ ПОЛУЧЕНИЯ И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ЕЕ ОСНОВЕ
|
JP6276894B2
(ja)
*
|
2014-06-10 |
2018-02-07 |
サイノファーム (チャンシュー) ファーマシューティカルズ リミテッド |
キナゾリン誘導体作製方法
|
WO2016011658A1
(en)
|
2014-07-25 |
2016-01-28 |
Novartis Ag |
Combination therapy
|
BR112017001695A2
(pt)
|
2014-07-31 |
2017-11-21 |
Novartis Ag |
terapia de combinação
|
SG10202100272RA
(en)
|
2014-08-28 |
2021-02-25 |
Eisai R&D Man Co Ltd |
High-purity quinoline derivative and method for manufacturing same
|
TWI567063B
(zh)
*
|
2014-09-05 |
2017-01-21 |
國立交通大學 |
用於促進癌細胞凋亡的化合物、其醫藥組成物及其用途
|
EP3189046B1
(en)
|
2014-09-05 |
2020-08-26 |
Genentech, Inc. |
Therapeutic compounds and uses thereof
|
CN107073125A
(zh)
|
2014-09-19 |
2017-08-18 |
基因泰克公司 |
Cbp/ep300和bet抑制剂用于治疗癌症的用途
|
JP6783230B2
(ja)
|
2014-10-10 |
2020-11-11 |
ジェネンテック, インコーポレイテッド |
ヒストンデメチラーゼのインヒビターとしてのピロリドンアミド化合物
|
ES2855075T3
(es)
|
2014-10-17 |
2021-09-23 |
Novartis Ag |
Combinación de ceritinib con un inhibidor de EGFR
|
RU2017119009A
(ru)
|
2014-11-03 |
2018-12-05 |
Дженентек, Инк. |
Анализы для обнаружения субпопуляций иммунных т-клеток и способы их применения
|
CN114381521A
(zh)
|
2014-11-03 |
2022-04-22 |
豪夫迈·罗氏有限公司 |
用于ox40激动剂治疗的功效预测和评估的方法和生物标志物
|
KR20170072343A
(ko)
|
2014-11-06 |
2017-06-26 |
제넨테크, 인크. |
Ox40 결합 효능제 및 tigit 억제제를 포함하는 병용 요법
|
MA40940A
(fr)
|
2014-11-10 |
2017-09-19 |
Constellation Pharmaceuticals Inc |
Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
|
WO2016077375A1
(en)
|
2014-11-10 |
2016-05-19 |
Genentech, Inc. |
Bromodomain inhibitors and uses thereof
|
MA40943A
(fr)
|
2014-11-10 |
2017-09-19 |
Constellation Pharmaceuticals Inc |
Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
|
BR112017010198A2
(pt)
|
2014-11-17 |
2017-12-26 |
Genentech Inc |
terapia de combinação compreendendo agonistas de ligação a ox40 e antagonistas de ligação ao eixo de pd-1
|
EP3632915A1
(en)
|
2014-11-27 |
2020-04-08 |
Genentech, Inc. |
4,5,6,7-tetrahydro-1 h-pyrazolo[4,3-c]pyridin-3-amine compounds as cbp and/or ep300 inhibitors
|
WO2016088858A1
(ja)
*
|
2014-12-04 |
2016-06-09 |
Delta-Fly Pharma株式会社 |
新規peg誘導体
|
US20180000827A1
(en)
|
2014-12-19 |
2018-01-04 |
Synthon B.V. |
Pharmaceutical composition comprising gefitinib
|
HK1243141A1
(zh)
|
2014-12-23 |
2018-07-06 |
豪夫迈.罗氏有限公司 |
用於治疗和诊断化学疗法抗性癌症的组合物和方法
|
JP6900314B2
(ja)
|
2014-12-24 |
2021-07-07 |
ジェネンテック, インコーポレイテッド |
膀胱癌の治療、診断、及び予後判定方法
|
WO2016109546A2
(en)
|
2014-12-30 |
2016-07-07 |
Genentech, Inc. |
Methods and compositions for prognosis and treatment of cancers
|
UA126268C2
(uk)
|
2015-01-06 |
2022-09-14 |
Арена Фармасьютікалз, Інк. |
СПОСОБИ ЛІКУВАННЯ СТАНІВ, ПОВ'ЯЗАНИХ З РЕЦЕПТОРОМ S1P<sub>1 </sub>
|
WO2016112111A1
(en)
|
2015-01-08 |
2016-07-14 |
The Board Of Trustees Of The Leland Stanford Junior University |
Factors and cells that provide for induction of bone, bone marrow, and cartilage
|
CN107406418B
(zh)
|
2015-01-09 |
2021-10-29 |
基因泰克公司 |
4,5-二氢咪唑衍生物及其作为组蛋白脱甲基酶(kdm2b)抑制剂的用途
|
EP3242874B1
(en)
|
2015-01-09 |
2018-10-31 |
Genentech, Inc. |
Pyridazinone derivatives and their use in the treatment of cancer
|
JP6855379B2
(ja)
|
2015-01-09 |
2021-04-07 |
ジェネンテック, インコーポレイテッド |
癌の処置のためのヒストンデメチラーゼkdm2bのインヒビターとしての(ピペリジン−3−イル)(ナフタレン−2−イル)メタノン誘導体および関連化合物
|
KR101635724B1
(ko)
*
|
2015-01-28 |
2016-07-05 |
일동제약주식회사 |
게피티닙의 개선된 제조방법
|
MA41414A
(fr)
|
2015-01-28 |
2017-12-05 |
Centre Nat Rech Scient |
Protéines de liaison agonistes d' icos
|
JP6709792B2
(ja)
|
2015-01-29 |
2020-06-17 |
ジェネンテック, インコーポレイテッド |
治療用化合物およびその使用
|
WO2016123387A1
(en)
|
2015-01-30 |
2016-08-04 |
Genentech, Inc. |
Therapeutic compounds and uses thereof
|
DK3263106T3
(da)
|
2015-02-25 |
2024-01-08 |
Eisai R&D Man Co Ltd |
Fremgangsmåde til undertrykkelse af bitterhed af quinolinderivat
|
MA41598A
(fr)
|
2015-02-25 |
2018-01-02 |
Constellation Pharmaceuticals Inc |
Composés thérapeutiques de pyridazine et leurs utilisations
|
KR20240064733A
(ko)
|
2015-03-04 |
2024-05-13 |
머크 샤프 앤드 돔 코포레이션 |
암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
|
EP3272746B1
(en)
*
|
2015-03-20 |
2019-12-25 |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Salts of quinazoline derivative and method for preparing same
|
CN107709364A
(zh)
|
2015-04-07 |
2018-02-16 |
豪夫迈·罗氏有限公司 |
具有激动剂活性的抗原结合复合体及使用方法
|
MX2017014381A
(es)
|
2015-05-12 |
2018-03-02 |
Genentech Inc |
Metodos terapeuticos y diagnosticos para cancer.
|
EP3708681A1
(en)
|
2015-05-29 |
2020-09-16 |
F. Hoffmann-La Roche AG |
Therapeutic and diagnostic methods for cancer
|
CA2985483A1
(en)
|
2015-06-08 |
2016-12-15 |
Genentech, Inc. |
Methods of treating cancer using anti-ox40 antibodies
|
AU2016274584A1
(en)
|
2015-06-08 |
2018-01-04 |
Genentech, Inc. |
Methods of treating cancer using anti-OX40 antibodies and PD-1 axis binding antagonists
|
BR112017027227B1
(pt)
|
2015-06-16 |
2023-12-12 |
Eisai R&D Management Co., Ltd |
Agente anti-câncer
|
WO2016205320A1
(en)
|
2015-06-17 |
2016-12-22 |
Genentech, Inc. |
Methods of treating locally advanced or metastatic breast cancers using pd-1 axis binding antagonists and taxanes
|
WO2016209809A1
(en)
|
2015-06-22 |
2016-12-29 |
Arena Pharmaceuticals, Inc. |
Crystalline l-arginine salt of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid(compound1) for use in sipi receptor-associated disorders
|
EP3795609B1
(en)
|
2015-07-01 |
2024-04-03 |
California Institute of Technology |
Cationic mucic acid polymer-based delivery systems
|
US20180230431A1
(en)
|
2015-08-07 |
2018-08-16 |
Glaxosmithkline Intellectual Property Development Limited |
Combination Therapy
|
RU2718048C2
(ru)
|
2015-08-20 |
2020-03-30 |
Эйсай Ар Энд Ди Менеджмент Ко., Лтд. |
Противоопухолевое терапевтическое средство
|
EP3341376B1
(en)
|
2015-08-26 |
2020-12-23 |
Fundación del Sector Público Estatal Centro Nacional de Investigaciones Oncológicas Carlos III (F.S.P. CNIO) |
Condensed tricyclic compounds as protein kinase inhibitors
|
KR20180050339A
(ko)
|
2015-09-04 |
2018-05-14 |
오비아이 파머 인코퍼레이티드 |
글리칸 어레이 및 사용 방법
|
WO2017044434A1
(en)
|
2015-09-11 |
2017-03-16 |
Sunshine Lake Pharma Co., Ltd. |
Substituted heteroaryl compounds and methods of use
|
GB201516905D0
(en)
|
2015-09-24 |
2015-11-11 |
Stratified Medical Ltd |
Treatment of Neurodegenerative diseases
|
IL319106A
(en)
|
2015-09-25 |
2025-04-01 |
Genentech Inc |
Anti-TIGIT antibodies and methods of use
|
CN105250228B
(zh)
*
|
2015-10-12 |
2017-10-24 |
山东罗欣药业集团股份有限公司 |
一种吉非替尼的片剂及其原料的制备方法
|
AU2016347881A1
(en)
|
2015-11-02 |
2018-05-10 |
Novartis Ag |
Dosage regimen for a phosphatidylinositol 3-kinase inhibitor
|
US20190256608A1
(en)
|
2015-12-01 |
2019-08-22 |
Glaxosmithkline Intellectual Property Development Limited |
Combination treatments and uses and methods thereof
|
EP3389662B1
(en)
|
2015-12-16 |
2021-12-01 |
Genentech, Inc. |
Process for the preparation of tricyclic pi3k inhibitor compounds and methods for using the same for the treatment of cancer
|
WO2017114735A1
(en)
|
2015-12-30 |
2017-07-06 |
Synthon B.V. |
Process for making crystalline form a of gefitinib
|
CN105503748A
(zh)
*
|
2015-12-31 |
2016-04-20 |
哈药集团技术中心 |
一种吉非替尼的制备方法
|
KR20180097615A
(ko)
|
2016-01-08 |
2018-08-31 |
에프. 호프만-라 로슈 아게 |
Pd-1 축 결합 길항물질 및 항-cea/항-cd3 이중특이성 항체를 사용하는 cea-양성 암의 치료 방법
|
KR102500659B1
(ko)
|
2016-02-29 |
2023-02-16 |
제넨테크, 인크. |
암에 대한 치료 및 진단 방법
|
US10980894B2
(en)
|
2016-03-29 |
2021-04-20 |
Obi Pharma, Inc. |
Antibodies, pharmaceutical compositions and methods
|
EP3436482A4
(en)
|
2016-03-29 |
2020-03-11 |
OBI Pharma, Inc. |
ANTIBODIES, PHARMACEUTICAL COMPOSITIONS AND METHODS
|
WO2017180864A1
(en)
|
2016-04-14 |
2017-10-19 |
Genentech, Inc. |
Anti-rspo3 antibodies and methods of use
|
WO2017180581A1
(en)
|
2016-04-15 |
2017-10-19 |
Genentech, Inc. |
Diagnostic and therapeutic methods for cancer
|
MX384141B
(es)
|
2016-04-15 |
2025-03-14 |
Genentech Inc |
Métodos para monitorear y terapias para usarse en tratar el cáncer.
|
CN109154027A
(zh)
|
2016-04-15 |
2019-01-04 |
豪夫迈·罗氏有限公司 |
用于监测和治疗癌症的方法
|
US11261187B2
(en)
|
2016-04-22 |
2022-03-01 |
Duke University |
Compounds and methods for targeting HSP90
|
US11583577B2
(en)
|
2016-04-22 |
2023-02-21 |
Obi Pharma, Inc. |
Cancer immunotherapy by immune activation or immune modulation via Globo series antigens
|
EP3454863A1
(en)
|
2016-05-10 |
2019-03-20 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Combinations therapies for the treatment of cancer
|
KR101796684B1
(ko)
*
|
2016-05-19 |
2017-11-10 |
건국대학교 산학협력단 |
케라틴 8 인산화 억제제를 포함하는 황반변성 예방 또는 치료용 약학 조성물 및 황반변성 치료제의 스크리닝 방법
|
EP3464286B1
(en)
|
2016-05-24 |
2021-08-18 |
Genentech, Inc. |
Pyrazolopyridine derivatives for the treatment of cancer
|
JP7160688B2
(ja)
|
2016-05-24 |
2022-10-25 |
ジェネンテック, インコーポレイテッド |
Cbp/ep300の複素環式インヒビターおよびがんの処置におけるそれらの使用
|
CN106045980B
(zh)
*
|
2016-06-03 |
2017-11-03 |
江苏开放大学 |
一种喹唑啉衍生物及其制备方法
|
WO2017214373A1
(en)
|
2016-06-08 |
2017-12-14 |
Genentech, Inc. |
Diagnostic and therapeutic methods for cancer
|
PL3468997T3
(pl)
|
2016-06-08 |
2024-12-16 |
Xencor, Inc. |
Leczenie chorób związanych z lgG4 przeciwciałami anty-CD19 wiążącymi się krzyżowo z CD32b
|
WO2018022933A1
(en)
|
2016-07-27 |
2018-02-01 |
Obi Pharma, Inc. |
Immunogenic/therapeutic glycan compositions and uses thereof
|
WO2018023121A1
(en)
|
2016-07-29 |
2018-02-01 |
Obi Pharma, Inc. |
Human antibodies, pharmaceutical compositions and methods
|
WO2018025221A1
(en)
|
2016-08-04 |
2018-02-08 |
Glaxosmithkline Intellectual Property Development Limited |
Anti-icos and anti-pd-1 antibody combination therapy
|
WO2018027204A1
(en)
|
2016-08-05 |
2018-02-08 |
Genentech, Inc. |
Multivalent and multiepitopic anitibodies having agonistic activity and methods of use
|
JP7250674B2
(ja)
|
2016-08-08 |
2023-04-03 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
がんの治療及び診断方法
|
WO2018039203A1
(en)
|
2016-08-23 |
2018-03-01 |
Oncopep, Inc. |
Peptide vaccines and durvalumab for treating multiple myeloma
|
WO2018039205A1
(en)
|
2016-08-23 |
2018-03-01 |
Oncopep, Inc. |
Peptide vaccines and durvalumab for treating breast cancer
|
CN106432202B
(zh)
*
|
2016-09-22 |
2019-04-02 |
郑州大学第一附属医院 |
喹唑啉类衍生物及其应用
|
WO2018060833A1
(en)
|
2016-09-27 |
2018-04-05 |
Novartis Ag |
Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib
|
AU2017335634A1
(en)
|
2016-09-27 |
2019-03-14 |
Cero Therapeutics, Inc. |
Chimeric engulfment receptor molecules
|
US10207998B2
(en)
|
2016-09-29 |
2019-02-19 |
Duke University |
Substituted benzimidazole and substituted benzothiazole inhibitors of transforming growth factor-β kinase and methods of use thereof
|
US10927083B2
(en)
|
2016-09-29 |
2021-02-23 |
Duke University |
Substituted benzimidazoles as inhibitors of transforming growth factor-β kinase
|
JP7579056B2
(ja)
|
2016-10-06 |
2024-11-07 |
ジェネンテック, インコーポレイテッド |
がんのための治療方法及び診断方法
|
WO2018078143A1
(en)
|
2016-10-28 |
2018-05-03 |
MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. |
Means and methods for determining efficacy of anti-egfr inhibitors in colorectal cancer (crc) therapy
|
EP3532091A2
(en)
|
2016-10-29 |
2019-09-04 |
H. Hoffnabb-La Roche Ag |
Anti-mic antibidies and methods of use
|
JP2019535731A
(ja)
|
2016-11-21 |
2019-12-12 |
オービーアイ ファーマ,インコーポレイテッド |
コンジュゲートさせた生物学的分子、医薬組成物及び方法
|
JP6858861B2
(ja)
|
2016-12-22 |
2021-04-14 |
アムジエン・インコーポレーテツド |
肺がん、膵臓がん、または大腸がんを治療するためのKRAS G12C阻害剤としての、ベンズイソチアゾール、イソチアゾロ[3,4−b]ピリジン、キナゾリン、フタラジン、ピリド[2,3−d]ピリダジンおよびピリド[2,3−d]ピリミジン誘導体
|
KR102539920B1
(ko)
|
2017-02-08 |
2023-06-05 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
종양-치료용 약제학적 조성물
|
ES2953595T3
(es)
|
2017-03-01 |
2023-11-14 |
Hoffmann La Roche |
Procedimientos diagnósticos y terapéuticos para el cáncer
|
US9980967B1
(en)
|
2017-03-16 |
2018-05-29 |
National Chiao Tung University |
Method for overcoming drug resistance of EGFR mutation and cancerous stemness of human non-small cell lung carcinoma
|
CN110505883A
(zh)
|
2017-04-13 |
2019-11-26 |
豪夫迈·罗氏有限公司 |
供治疗癌症的方法中使用的白介素-2免疫缀合物,cd40激动剂,和任选地pd-1轴结合拮抗剂
|
SG11201910100PA
(en)
|
2017-05-16 |
2019-11-28 |
Eisai R&D Man Co Ltd |
Treatment of hepatocellular carcinoma
|
JOP20190272A1
(ar)
|
2017-05-22 |
2019-11-21 |
Amgen Inc |
مثبطات kras g12c وطرق لاستخدامها
|
US11674962B2
(en)
|
2017-07-21 |
2023-06-13 |
Genentech, Inc. |
Therapeutic and diagnostic methods for cancer
|
KR102713874B1
(ko)
|
2017-08-11 |
2024-10-10 |
제넨테크, 인크. |
항-cd8 항체 및 이의 용도
|
MA50077A
(fr)
|
2017-09-08 |
2020-07-15 |
Amgen Inc |
Inhibiteurs de kras g12c et leurs procédés d'utilisation
|
JP7530829B2
(ja)
|
2017-09-08 |
2024-08-08 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
がんの診断及び治療方法
|
CA3073421A1
(en)
|
2017-09-26 |
2019-04-04 |
Daniel Mark COREY |
Chimeric engulfment receptor molecules and methods of use
|
WO2019083960A1
(en)
|
2017-10-24 |
2019-05-02 |
Oncopep, Inc. |
PEPTIDE VACCINES AND HDAC INHIBITORS FOR THE TREATMENT OF MULTIPLE MYELOMA
|
CN111465411A
(zh)
|
2017-10-24 |
2020-07-28 |
恩科佩普股份有限公司 |
用于治疗乳腺癌的肽疫苗和派姆单抗
|
EP3710001B1
(en)
|
2017-10-27 |
2025-06-18 |
University Of Virginia Patent Foundation |
Compounds and methods for regulating, limiting, or inhibiting avil expression
|
CN109721552B
(zh)
*
|
2017-10-30 |
2022-09-20 |
上海北卡医药技术有限公司 |
一种吉非替尼的制备方法
|
MX2020004567A
(es)
|
2017-11-06 |
2020-08-13 |
Genentech Inc |
Metodos diagnosticos y terapeuticos para el cancer.
|
US10683297B2
(en)
|
2017-11-19 |
2020-06-16 |
Calitor Sciences, Llc |
Substituted heteroaryl compounds and methods of use
|
US11708335B2
(en)
|
2017-12-18 |
2023-07-25 |
Sterngreene, Inc. |
Pyrimidine compounds useful as tyrosine kinase inhibitors
|
AU2017444054B2
(en)
|
2017-12-21 |
2021-10-07 |
Hefei Institutes Of Physical Science, Chinese Academy Of Sciences |
Class of pyrimidine derivative kinase inhibitors
|
JP7236164B2
(ja)
|
2018-01-15 |
2023-03-09 |
エピアクシス セラピューティクス プロプライエタリー リミテッド |
治療法に対する応答を予測する薬剤及び方法
|
AU2019209960B2
(en)
|
2018-01-20 |
2023-11-23 |
Sunshine Lake Pharma Co., Ltd. |
Substituted aminopyrimidine compounds and methods of use
|
IL276028B2
(en)
|
2018-01-26 |
2025-02-01 |
Exelixis Inc |
Compounds for the treatment of kinase-dependent disorders
|
AU2019212801B2
(en)
|
2018-01-26 |
2024-07-04 |
Exelixis, Inc. |
Compounds for the treatment of kinase-dependent disorders
|
CN111936487B
(zh)
|
2018-01-26 |
2024-07-09 |
埃克塞里艾克西斯公司 |
用于治疗激酶依赖性病症的化合物
|
JP7391027B2
(ja)
|
2018-02-26 |
2023-12-04 |
ジェネンテック, インコーポレイテッド |
抗tigit及び抗pd-l1アンタゴニスト抗体による治療のための投薬
|
WO2019191340A1
(en)
|
2018-03-28 |
2019-10-03 |
Cero Therapeutics, Inc. |
Cellular immunotherapy compositions and uses thereof
|
US20210024607A1
(en)
|
2018-03-28 |
2021-01-28 |
Cero Therapeutics, Inc. |
Expression vectors for chimeric engulfment receptors, genetically modified host cells, and uses thereof
|
US12291557B2
(en)
|
2018-03-28 |
2025-05-06 |
Cero Therapeutics Holdings, Inc. |
Chimeric TIM4 receptors and uses thereof
|
BR112020020246A8
(pt)
|
2018-04-05 |
2022-10-18 |
Sumitomo Dainippon Pharma Oncology Inc |
Inibidores de cinase axl e uso dos mesmos
|
ES2995514T3
(en)
|
2018-05-04 |
2025-02-10 |
Amgen Inc |
Kras g12c inhibitors and methods of using the same
|
MA52501A
(fr)
|
2018-05-04 |
2021-03-10 |
Amgen Inc |
Inhibiteurs de kras g12c et leurs procédés d'utilisation
|
CN108395410A
(zh)
*
|
2018-05-09 |
2018-08-14 |
日照市普达医药科技有限公司 |
一种苯胺喹唑啉化合物及其在抗肿瘤药物中的应用
|
MX2020011907A
(es)
|
2018-05-10 |
2021-01-29 |
Amgen Inc |
Inhibidores de kras g12c para el tratamiento de cancer.
|
EP3797173A2
(en)
|
2018-05-21 |
2021-03-31 |
Nanostring Technologies, Inc. |
Molecular gene signatures and methods of using same
|
ES2938987T3
(es)
|
2018-06-01 |
2023-04-18 |
Amgen Inc |
Inhibidores de KRAS G12c y métodos de uso de los mismos
|
JP2021525802A
(ja)
|
2018-06-01 |
2021-09-27 |
コーネル・ユニバーシティーCornell University |
Pi3kに関連する疾患または障害に対する併用療法
|
MA52778A
(fr)
|
2018-06-06 |
2021-04-21 |
Arena Pharm Inc |
Méthodes de traitement de troubles associés au récepteur s1p1
|
US20190375749A1
(en)
|
2018-06-11 |
2019-12-12 |
Amgen Inc. |
Kras g12c inhibitors and methods of using the same
|
CA3100390A1
(en)
|
2018-06-12 |
2020-03-12 |
Amgen Inc. |
Kras g12c inhibitors encompassing piperazine ring and use thereof in the treatment of cancer
|
JP7483193B2
(ja)
|
2018-06-13 |
2024-05-15 |
カリフォルニア・インスティテュート・オブ・テクノロジー |
血脳バリアを越えるためのナノ粒子とそれを用いた治療法
|
JP7399895B2
(ja)
|
2018-06-23 |
2023-12-18 |
ジェネンテック, インコーポレイテッド |
Pd-1軸結合拮抗薬、白金剤、およびトポイソメラーゼii阻害剤で肺癌を治療する方法
|
WO2020006176A1
(en)
|
2018-06-27 |
2020-01-02 |
Obi Pharma, Inc. |
Glycosynthase variants for glycoprotein engineering and methods of use
|
BR112021000673A2
(pt)
|
2018-07-18 |
2021-04-20 |
Genentech, Inc. |
métodos para tratar um indivíduo com câncer de pulmão, kits, anticorpo anti-pd-l1 e composições
|
EP3826988A4
(en)
|
2018-07-24 |
2023-03-22 |
Hygia Pharmaceuticals, LLC |
COMPOUNDS, DERIVATIVES AND ANALOGUES FOR CANCER
|
EP3826684A4
(en)
|
2018-07-26 |
2022-04-06 |
Sumitomo Dainippon Pharma Oncology, Inc. |
METHODS OF TREATMENT OF DISEASES ASSOCIATED WITH ABNORMAL ACVR1 EXPRESSION AND ACVR1 INHIBITORS FOR USE IN THE SAME
|
EP3847154A1
(en)
|
2018-09-03 |
2021-07-14 |
F. Hoffmann-La Roche AG |
Carboxamide and sulfonamide derivatives useful as tead modulators
|
CN112955747A
(zh)
|
2018-09-19 |
2021-06-11 |
豪夫迈·罗氏有限公司 |
膀胱癌的治疗和诊断方法
|
CA3111809A1
(en)
|
2018-09-21 |
2020-03-26 |
Genentech, Inc. |
Diagnostic methods for triple-negative breast cancer
|
US20210393632A1
(en)
|
2018-10-04 |
2021-12-23 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Egfr inhibitors for treating keratodermas
|
US12404540B2
(en)
|
2018-10-17 |
2025-09-02 |
The University Of Queensland |
Epigenetic biomarker and uses therefor
|
JP2022512744A
(ja)
|
2018-10-18 |
2022-02-07 |
ジェネンテック, インコーポレイテッド |
肉腫様腎臓がんのための診断および治療方法
|
JP7516029B2
(ja)
|
2018-11-16 |
2024-07-16 |
アムジエン・インコーポレーテツド |
Kras g12c阻害剤化合物の重要な中間体の改良合成法
|
US11053226B2
(en)
|
2018-11-19 |
2021-07-06 |
Amgen Inc. |
KRAS G12C inhibitors and methods of using the same
|
JP7377679B2
(ja)
|
2018-11-19 |
2023-11-10 |
アムジエン・インコーポレーテツド |
がん治療のためのkrasg12c阻害剤及び1種以上の薬学的に活性な追加の薬剤を含む併用療法
|
US12180207B2
(en)
|
2018-12-19 |
2024-12-31 |
Array Biopharma Inc. |
Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of FGFR tyrosine kinases
|
US12351571B2
(en)
|
2018-12-19 |
2025-07-08 |
Array Biopharma Inc. |
Substituted quinoxaline compounds as inhibitors of FGFR tyrosine kinases
|
MX2021007104A
(es)
|
2018-12-20 |
2021-08-11 |
Amgen Inc |
Inhibidores de kif18a.
|
PH12021551409A1
(en)
|
2018-12-20 |
2022-05-16 |
Amgen Inc |
Kif18a inhibitors
|
MX2021007157A
(es)
|
2018-12-20 |
2021-08-16 |
Amgen Inc |
Heteroarilamidas utiles como inhibidores de kif18a.
|
CA3123227A1
(en)
|
2018-12-20 |
2020-06-25 |
Amgen Inc. |
Heteroaryl amides useful as kif18a inhibitors
|
CN113195000A
(zh)
|
2018-12-21 |
2021-07-30 |
第一三共株式会社 |
抗体-药物缀合物和激酶抑制剂的组合
|
WO2020160365A1
(en)
|
2019-02-01 |
2020-08-06 |
Glaxosmithkline Intellectual Property Development Limited |
Belantamab mafodotin in combination with pembrolizumab for treating cancer
|
CN113396230A
(zh)
|
2019-02-08 |
2021-09-14 |
豪夫迈·罗氏有限公司 |
癌症的诊断和治疗方法
|
KR20210133237A
(ko)
|
2019-02-27 |
2021-11-05 |
제넨테크, 인크. |
항-tigit 및 항-cd20 또는 항-cd38 항체로 치료를 위한 투약
|
WO2020172712A1
(en)
|
2019-02-27 |
2020-09-03 |
Epiaxis Therapeutics Pty Ltd |
Methods and agents for assessing t-cell function and predicting response to therapy
|
JP2022522778A
(ja)
|
2019-03-01 |
2022-04-20 |
レボリューション メディシンズ インコーポレイテッド |
二環式ヘテロシクリル化合物及びその使用
|
EP3931195A1
(en)
|
2019-03-01 |
2022-01-05 |
Revolution Medicines, Inc. |
Bicyclic heteroaryl compounds and uses thereof
|
WO2020223233A1
(en)
|
2019-04-30 |
2020-11-05 |
Genentech, Inc. |
Prognostic and therapeutic methods for colorectal cancer
|
CN114269376A
(zh)
|
2019-05-03 |
2022-04-01 |
豪夫迈·罗氏有限公司 |
用抗pd-l1抗体治疗癌症的方法
|
EP3738593A1
(en)
|
2019-05-14 |
2020-11-18 |
Amgen, Inc |
Dosing of kras inhibitor for treatment of cancers
|
MX2021014126A
(es)
|
2019-05-21 |
2022-01-04 |
Amgen Inc |
Formas en estado solido.
|
CA3143211A1
(en)
|
2019-06-26 |
2020-12-30 |
Glaxosmithkline Intellectual Property Development Limited |
Il1rap binding proteins
|
CN112300279A
(zh)
|
2019-07-26 |
2021-02-02 |
上海复宏汉霖生物技术股份有限公司 |
针对抗cd73抗体和变体的方法和组合物
|
WO2021026101A1
(en)
|
2019-08-02 |
2021-02-11 |
Amgen Inc. |
Kif18a inhibitors
|
JP2022542392A
(ja)
|
2019-08-02 |
2022-10-03 |
アムジエン・インコーポレーテツド |
Kif18a阻害剤としてのピリジン誘導体
|
MX2022001295A
(es)
|
2019-08-02 |
2022-02-22 |
Amgen Inc |
Inhibidores de kif18a.
|
AU2020324406A1
(en)
|
2019-08-02 |
2022-03-17 |
Amgen Inc. |
KIF18A inhibitors
|
AR119887A1
(es)
|
2019-09-04 |
2022-01-19 |
Genentech Inc |
Agentes de unión a cd8 y sus usos
|
WO2021043961A1
(en)
|
2019-09-06 |
2021-03-11 |
Glaxosmithkline Intellectual Property Development Limited |
Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and chemotherapy
|
WO2021046293A1
(en)
|
2019-09-06 |
2021-03-11 |
Glaxosmithkline Intellectual Property Development Limited |
Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and tremelimumab
|
EP4034532A1
(en)
|
2019-09-26 |
2022-08-03 |
Exelixis, Inc. |
Pyridone compounds and methods of use in the modulation of a protein kinase
|
JP2022548978A
(ja)
|
2019-09-27 |
2022-11-22 |
ジェネンテック, インコーポレイテッド |
薬抗tigit及び抗pd-l1アンタゴニスト抗体を用いた処置のための投薬
|
EP4038097A1
(en)
|
2019-10-03 |
2022-08-10 |
Cero Therapeutics, Inc. |
Chimeric tim4 receptors and uses thereof
|
AU2020369569A1
(en)
|
2019-10-24 |
2022-04-14 |
Amgen Inc. |
Pyridopyrimidine derivatives useful as KRAS G12C and KRAS G12D inhibitors in the treatment of cancer
|
JP2023511472A
(ja)
|
2019-10-29 |
2023-03-20 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
がんの治療のための二官能性化合物
|
TW202132314A
(zh)
|
2019-11-04 |
2021-09-01 |
美商銳新醫藥公司 |
Ras抑制劑
|
WO2021091982A1
(en)
|
2019-11-04 |
2021-05-14 |
Revolution Medicines, Inc. |
Ras inhibitors
|
CN115873020B
(zh)
|
2019-11-04 |
2025-06-13 |
锐新医药公司 |
Ras抑制剂
|
KR20220092580A
(ko)
|
2019-11-06 |
2022-07-01 |
제넨테크, 인크. |
혈액암의 치료를 위한 진단과 치료 방법
|
MX2022005525A
(es)
|
2019-11-08 |
2022-06-08 |
Revolution Medicines Inc |
Compuestos de heteroarilo bicíclicos y usos de estos.
|
US20210161897A1
(en)
|
2019-11-12 |
2021-06-03 |
Astrazeneca Ab |
Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
|
MX2022005775A
(es)
|
2019-11-13 |
2022-06-09 |
Genentech Inc |
Compuestos terapeuticos y metodos de uso.
|
AR120456A1
(es)
|
2019-11-14 |
2022-02-16 |
Amgen Inc |
Síntesis mejorada del compuesto inhibidor de g12c de kras
|
AU2020381492A1
(en)
|
2019-11-14 |
2022-05-26 |
Amgen Inc. |
Improved synthesis of KRAS G12C inhibitor compound
|
US20220395553A1
(en)
|
2019-11-14 |
2022-12-15 |
Cohbar, Inc. |
Cxcr4 antagonist peptides
|
EP4065231A1
(en)
|
2019-11-27 |
2022-10-05 |
Revolution Medicines, Inc. |
Covalent ras inhibitors and uses thereof
|
BR112022011357A2
(pt)
|
2019-12-13 |
2022-08-23 |
Genentech Inc |
Anticorpos isolado, um ou mais ácidos nucleicos isolados, um ou mais vetores, uma ou mais células hospedeiras, composição, kit, uso do anticorpo, métodos para produzir o anticorpo e método para tratar ou retardar a progressão de um câncer ly6g6d positivo
|
WO2021127404A1
(en)
|
2019-12-20 |
2021-06-24 |
Erasca, Inc. |
Tricyclic pyridones and pyrimidones
|
MX2022008305A
(es)
|
2020-01-07 |
2022-08-08 |
Revolution Medicines Inc |
Dosificacion de inhibidores de shp2 y metodos de tratamiento del cancer.
|
AU2021211871A1
(en)
|
2020-01-20 |
2022-09-08 |
Astrazeneca Ab |
Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
|
JP2023511595A
(ja)
|
2020-01-27 |
2023-03-20 |
ジェネンテック, インコーポレイテッド |
抗tigitアンタゴニスト抗体を用いたがんを処置するための方法
|
WO2021194481A1
(en)
|
2020-03-24 |
2021-09-30 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
WO2022050954A1
(en)
|
2020-09-04 |
2022-03-10 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
EP4096718A1
(en)
|
2020-01-28 |
2022-12-07 |
GlaxoSmithKline Intellectual Property Development Limited |
Combination treatments and uses and methods thereof
|
WO2021177980A1
(en)
|
2020-03-06 |
2021-09-10 |
Genentech, Inc. |
Combination therapy for cancer comprising pd-1 axis binding antagonist and il6 antagonist
|
WO2021233534A1
(en)
|
2020-05-20 |
2021-11-25 |
Pvac Medical Technologies Ltd |
Use of substance and pharmaceutical composition thereof, and medical treatments or uses thereof
|
WO2021185844A1
(en)
|
2020-03-16 |
2021-09-23 |
Pvac Medical Technologies Ltd |
Use of substance and pharmaceutical composition thereof, and medical treatments or uses thereof
|
CN115380026B
(zh)
*
|
2020-03-17 |
2023-11-07 |
南京明德新药研发有限公司 |
蛋白降解调节剂与其使用方法
|
WO2021202959A1
(en)
|
2020-04-03 |
2021-10-07 |
Genentech, Inc. |
Therapeutic and diagnostic methods for cancer
|
EP4136228A4
(en)
|
2020-04-15 |
2024-09-11 |
California Institute of Technology |
THERMAL REGULATION OF T-CELL IMMUNOTHERAPY BY MOLECULAR AND PHYSICAL ACTUATION
|
CN115885050A
(zh)
|
2020-04-28 |
2023-03-31 |
基因泰克公司 |
用于非小细胞肺癌免疫疗法的方法和组合物
|
CN113801068B
(zh)
*
|
2020-06-15 |
2024-10-11 |
山东新时代药业有限公司 |
一种吉非替尼的有机酸盐
|
IL299039A
(en)
|
2020-06-16 |
2023-02-01 |
Genentech Inc |
Methods and preparations for the treatment of triple-negative breast cancer
|
EP4168118A1
(en)
|
2020-06-18 |
2023-04-26 |
Genentech, Inc. |
Treatment with anti-tigit antibodies and pd-1 axis binding antagonists
|
TW202214253A
(zh)
|
2020-06-18 |
2022-04-16 |
美商銳新醫藥公司 |
延遲、預防及治療對ras抑制劑之後天抗性之方法
|
EP4172628A1
(en)
|
2020-06-30 |
2023-05-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting the risk of recurrence and/or death of patients suffering from a solid cancer after preoperative adjuvant therapy and radical surgery
|
JP2023531305A
(ja)
|
2020-06-30 |
2023-07-21 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
術前補助療法後の固形癌患者の再発及び/又は死亡のリスクを予測するための方法。
|
US11787775B2
(en)
|
2020-07-24 |
2023-10-17 |
Genentech, Inc. |
Therapeutic compounds and methods of use
|
WO2022031749A1
(en)
|
2020-08-03 |
2022-02-10 |
Genentech, Inc. |
Diagnostic and therapeutic methods for lymphoma
|
EP4192509A1
(en)
|
2020-08-05 |
2023-06-14 |
Ellipses Pharma Ltd |
Treatment of cancer using a cyclodextrin-containing polymer-topoisomerase inhibitor conjugate and a parp inhibitor
|
EP4196612A1
(en)
|
2020-08-12 |
2023-06-21 |
Genentech, Inc. |
Diagnostic and therapeutic methods for cancer
|
WO2022036287A1
(en)
|
2020-08-14 |
2022-02-17 |
Cero Therapeutics, Inc. |
Anti-cd72 chimeric receptors and uses thereof
|
WO2022036285A1
(en)
|
2020-08-14 |
2022-02-17 |
Cero Therapeutics, Inc. |
Compositions and methods for treating cancer with chimeric tim receptors in combination with inhibitors of poly (adp-ribose) polymerase
|
WO2022036265A1
(en)
|
2020-08-14 |
2022-02-17 |
Cero Therapeutics, Inc. |
Chimeric tim receptors and uses thereof
|
KR20230078657A
(ko)
|
2020-08-27 |
2023-06-02 |
에노시 테라퓨틱스 코퍼레이션 |
자가면역 질환 및 암을 치료하기 위한 방법 및 조성물
|
WO2022047259A1
(en)
|
2020-08-28 |
2022-03-03 |
California Institute Of Technology |
Synthetic mammalian signaling circuits for robust cell population control
|
IL301062A
(en)
|
2020-09-03 |
2023-05-01 |
Revolution Medicines Inc |
Use of sos1 inhibitors to treat malignancies with shp2 mutations
|
US11690915B2
(en)
|
2020-09-15 |
2023-07-04 |
Revolution Medicines, Inc. |
Ras inhibitors
|
EP4217071A1
(en)
|
2020-09-23 |
2023-08-02 |
Erasca, Inc. |
Tricyclic pyridones and pyrimidones
|
CN116406291A
(zh)
|
2020-10-05 |
2023-07-07 |
基因泰克公司 |
用抗fcrh5/抗cd3双特异性抗体进行治疗的给药
|
TW202237638A
(zh)
|
2020-12-09 |
2022-10-01 |
日商武田藥品工業股份有限公司 |
烏苷酸環化酶c(gcc)抗原結合劑之組成物及其使用方法
|
US20230107642A1
(en)
|
2020-12-18 |
2023-04-06 |
Erasca, Inc. |
Tricyclic pyridones and pyrimidones
|
US20240051956A1
(en)
|
2020-12-22 |
2024-02-15 |
Qilu Regor Therapeutics Inc. |
Sos1 inhibitors and uses thereof
|
CN112321814B
(zh)
*
|
2020-12-30 |
2021-03-23 |
广州初曲科技有限公司 |
一种吉非替尼艾地苯醌轭合物的制备及用途
|
MX2023009379A
(es)
|
2021-02-12 |
2023-10-10 |
Hoffmann La Roche |
Derivados de tetrahidroazepina biciclicos para el tratamiento del cancer.
|
EP4294804A1
(en)
|
2021-02-19 |
2023-12-27 |
Exelixis, Inc. |
Pyridone compounds and methods of use
|
IL305411A
(en)
|
2021-02-26 |
2023-10-01 |
Kelonia Therapeutics Inc |
Lymphocyte targeted lentiviral vectors
|
CN117500811A
(zh)
|
2021-05-05 |
2024-02-02 |
锐新医药公司 |
共价ras抑制剂及其用途
|
AU2022270116A1
(en)
|
2021-05-05 |
2023-12-21 |
Revolution Medicines, Inc. |
Ras inhibitors
|
CN117616031A
(zh)
|
2021-05-05 |
2024-02-27 |
锐新医药公司 |
用于治疗癌症的ras抑制剂
|
KR20240026948A
(ko)
|
2021-05-25 |
2024-02-29 |
에라스카, 아이엔씨. |
황 함유 헤테로방향족 트리사이클릭 kras 억제제
|
US20240293558A1
(en)
|
2021-06-16 |
2024-09-05 |
Erasca, Inc. |
Kras inhibitor conjugates
|
CN113527266A
(zh)
*
|
2021-06-23 |
2021-10-22 |
上海健康医学院 |
一种靶向fap的双氧水响应的前药及其制备方法与应用
|
CN113336742B
(zh)
|
2021-06-29 |
2022-05-10 |
山东金吉利新材料有限公司 |
一种马来酸吡咯替尼中间体的合成方法
|
CA3226019A1
(en)
|
2021-07-20 |
2023-01-26 |
Ags Therapeutics Sas |
Extracellular vesicles from microalgae, their preparation, and uses
|
JP2024529474A
(ja)
|
2021-07-28 |
2024-08-06 |
セロ・セラピューティクス・インコーポレイテッド |
キメラTim4受容体およびその使用
|
EP4384522A1
(en)
|
2021-08-10 |
2024-06-19 |
Erasca, Inc. |
Selective kras inhibitors
|
AR127308A1
(es)
|
2021-10-08 |
2024-01-10 |
Revolution Medicines Inc |
Inhibidores ras
|
CN113845485B
(zh)
*
|
2021-10-22 |
2023-03-14 |
湖南中医药大学 |
氨基酸衍生物及其制备方法和应用
|
WO2023097195A1
(en)
|
2021-11-24 |
2023-06-01 |
Genentech, Inc. |
Therapeutic indazole compounds and methods of use in the treatment of cancer
|
WO2023097194A2
(en)
|
2021-11-24 |
2023-06-01 |
Genentech, Inc. |
Therapeutic compounds and methods of use
|
WO2023114954A1
(en)
|
2021-12-17 |
2023-06-22 |
Genzyme Corporation |
Pyrazolopyrazine compounds as shp2 inhibitors
|
WO2023144127A1
(en)
|
2022-01-31 |
2023-08-03 |
Ags Therapeutics Sas |
Extracellular vesicles from microalgae, their biodistribution upon administration, and uses
|
EP4227307A1
(en)
|
2022-02-11 |
2023-08-16 |
Genzyme Corporation |
Pyrazolopyrazine compounds as shp2 inhibitors
|
JP2025510572A
(ja)
|
2022-03-08 |
2025-04-15 |
レボリューション メディシンズ インコーポレイテッド |
免疫不応性肺癌を治療するための方法
|
CN119278041A
(zh)
|
2022-03-31 |
2025-01-07 |
阿斯利康(瑞典)有限公司 |
用于治疗癌症的与akt抑制剂组合的表皮生长因子受体(egfr)酪氨酸激酶抑制剂
|
CN119487067A
(zh)
|
2022-04-01 |
2025-02-18 |
基因泰克公司 |
用抗fcrh5/抗cd3双特异性抗体进行治疗的给药
|
WO2023219613A1
(en)
|
2022-05-11 |
2023-11-16 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
IL317449A
(en)
|
2022-06-07 |
2025-02-01 |
Genentech Inc |
Method for determining the efficacy of a lung cancer treatment comprising an anti-PD-L1 antagonist and an anti-TIGIT antibody-antagonist
|
JP2025521232A
(ja)
|
2022-06-10 |
2025-07-08 |
レボリューション メディシンズ インコーポレイテッド |
大環状ras阻害剤
|
CN119421895A
(zh)
|
2022-06-27 |
2025-02-11 |
阿斯利康(瑞典)有限公司 |
涉及用于治疗癌症的表皮生长因子受体酪氨酸激酶抑制剂的组合
|
TW202417042A
(zh)
|
2022-07-13 |
2024-05-01 |
美商建南德克公司 |
用抗fcrh5/抗cd3雙特異性抗體進行治療之給藥
|
JP2025523845A
(ja)
|
2022-07-19 |
2025-07-25 |
ジェネンテック, インコーポレイテッド |
抗fcrh5/抗cd3二重特異性抗体による処置のための投薬
|
CN119816589A
(zh)
|
2022-08-02 |
2025-04-11 |
国立大学法人北海道大学 |
使用细胞器复合体改善细胞疗法的方法
|
CN119677732A
(zh)
|
2022-08-11 |
2025-03-21 |
豪夫迈·罗氏有限公司 |
双环四氢氮杂䓬衍生物
|
PE20250876A1
(es)
|
2022-08-11 |
2025-03-28 |
Hoffmann La Roche |
Derivados biciclicos de tetrahidrotiazepina
|
PE20251399A1
(es)
|
2022-08-11 |
2025-05-22 |
Hoffmann La Roche |
Derivados de tetrahidrotiazepina biciclicos
|
AR130169A1
(es)
|
2022-08-11 |
2024-11-13 |
Hoffmann La Roche |
Derivados de tetrahidrotiazepina bicíclicos
|
CN120359029A
(zh)
|
2022-10-14 |
2025-07-22 |
黑钻治疗公司 |
使用异喹啉或6-氮杂-喹啉衍生物治疗癌症的方法
|
WO2024085242A2
(en)
|
2022-10-21 |
2024-04-25 |
Kawasaki Institute Of Industrial Promotion |
Non-fouling or super stealth vesicle
|
WO2024088808A1
(en)
|
2022-10-24 |
2024-05-02 |
Ags Therapeutics Sas |
Extracellular vesicles from microalgae, their biodistribution upon intranasal administration, and uses thereof
|
AU2023367741A1
(en)
|
2022-10-25 |
2025-05-01 |
Genentech, Inc. |
Therapeutic and diagnostic methods for multiple myeloma
|
TW202434206A
(zh)
|
2023-02-17 |
2024-09-01 |
美商伊瑞斯卡公司 |
Kras抑制劑
|
WO2024206858A1
(en)
|
2023-03-30 |
2024-10-03 |
Revolution Medicines, Inc. |
Compositions for inducing ras gtp hydrolysis and uses thereof
|
WO2024211712A1
(en)
|
2023-04-07 |
2024-10-10 |
Revolution Medicines, Inc. |
Condensed macrocyclic compounds as ras inhibitors
|
AR132338A1
(es)
|
2023-04-07 |
2025-06-18 |
Revolution Medicines Inc |
Inhibidores de ras
|
US20240352038A1
(en)
|
2023-04-14 |
2024-10-24 |
Revolution Medicines, Inc. |
Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof
|
TW202446388A
(zh)
|
2023-04-14 |
2024-12-01 |
美商銳新醫藥公司 |
Ras抑制劑之結晶形式、含有其之組合物及其使用方法
|
TW202508595A
(zh)
|
2023-05-04 |
2025-03-01 |
美商銳新醫藥公司 |
用於ras相關疾病或病症之組合療法
|
WO2024233341A1
(en)
|
2023-05-05 |
2024-11-14 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
TW202504641A
(zh)
|
2023-06-08 |
2025-02-01 |
美商建南德克公司 |
用於淋巴瘤之診斷及治療方法的巨噬細胞特徵
|
WO2025024257A1
(en)
|
2023-07-21 |
2025-01-30 |
Genentech, Inc. |
Diagnostic and therapeutic methods for cancer
|
US20250049810A1
(en)
|
2023-08-07 |
2025-02-13 |
Revolution Medicines, Inc. |
Methods of treating a ras protein-related disease or disorder
|
TW202515614A
(zh)
|
2023-08-25 |
2025-04-16 |
美商建南德克公司 |
治療非小細胞肺癌之方法及組成物
|
WO2025080946A2
(en)
|
2023-10-12 |
2025-04-17 |
Revolution Medicines, Inc. |
Ras inhibitors
|
WO2025137507A1
(en)
|
2023-12-22 |
2025-06-26 |
Regor Pharmaceuticals, Inc. |
Sos1 inhibitors and uses thereof
|
WO2025171296A1
(en)
|
2024-02-09 |
2025-08-14 |
Revolution Medicines, Inc. |
Ras inhibitors
|
WO2025176847A1
(en)
|
2024-02-21 |
2025-08-28 |
Ags Therapeutics Sas |
Ocular delivery of active agents via microalgae extracellular vesicles
|